

**Supplementary table 1.** The examples of prescription drug-laboratory test interactions (DLTIs)

ATC Code (1)	Drug	Analyte	Mechanism of interference, number of patients/participants in the study (N)	Reference
<b>A Alimentary Tract and Metabolism</b>				
<b>A02 Drugs for Acid Related Disorders</b>				
<b>A02B Drugs for Peptic Ulcer And Gastro-Oesophageal Reflux Disease (Gord)</b>				
<b>A02BA H<sub>2</sub>-receptor Antagonists</b>				
<b>A02BA01</b>	Cimetidine	Bilirubin (total) (+)	Cholestatic hepatic injury (1/94)	(2,3)
		Creatinine (+)	Inhibition of tubular secretion (13)	(4,5)
<b>A02BA02</b>	Ranitidine	Creatinine (+)	Inhibition of tubular secretion (29)	(6)
<b>A02BC Proton Pump Inhibitors</b>				
<b>A02BC01</b>	Omeprazole	ALT (+)	Liver injury (1/899)	(7,8)
<b>A05 Bile and Liver Therapy</b>				
<b>A05A Bile Therapy</b>				
<b>A05AA Bile Acids and Derivatives</b>				
<b>A05AA01</b>	Chenodeoxycholic acid	Triglycerides (-)	Inhibition of hepatic synthesis (10)	(9)
		Total Cholesterol (-)	Increased bile acid production (17)	(10)
<b>A05AA02</b>	Ursodeoxycholic acid	LDL (-)	Increase in receptor-dependent LDL uptake by the liver (17)	(10)
<b>A08 Antiobesity Preparations, Excl. Diet Products</b>				
<b>A08AA Centrally Acting Antiobesity Products</b>				
<b>A08AA62</b>	Bupropion	ALT (+)	Liver injury (5/899)	(7,8)
<b>A08AB01</b>	Orlistat	Lp(a) (-)	ND (50)	(11)

		Uric Acid (-)	The interaction between uric acid and adiposity factors (50)	(11)
<b>A10 Drugs Used in Diabetes</b>				
<b>A10B Blood Glucose Lowering Drugs, Excl. Insulins</b>				
<b>A10BA Biguanides</b>				
		Lp(a) (-)	ND (50)	(11,12)
<b>A10BA02</b>	Metformin	Uric Acid (-)	Urinary uric acid clearance appears to increase with higher insulin sensitivity (50)	(11)
		CRP (-)	ND (21)	(13,14)
<b>A10BB Sulfonylureas</b>				
<b>A10BB12</b>	Glimepiride	CRP (-)	ND (20)	(15)
<b>A10BB31</b>	Acetohexamide	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(5)
<b>A10BG Thiazolidinediones</b>				
<b>A10BG01</b>	Troglitazone	Lp(a) (+)	ND (16)	(16)
<b>A10BG02</b>	Rosiglitazone	Bilirubin (total) (+)	Liver injury (CR)	(17)
		CRP (-)	ND (50)	(18,19)
		Total Cholesterol (-)	ND (20)	(20)
		Triglycerides (-)	Increased lipoprotein lipase-mediated lipolysis (20)	(20)
<b>A10BG03</b>	Pioglitazone	HDL (+)	Upregulation of Apo-AI and ABCA1 (20)	(20)
		LDL (-)	ND (20)	(20)
		CRP (-)	Prevention of TNF- $\alpha$ action at receptor level (20)	(20)

<b>A10BH Dipeptidyl Peptidase 4 (DPP-4) Inhibitors</b>				
<b>A10BH01</b>	Sitagliptin	CRP (-)	Inhibition of Interleukin-6 (24)	(21)
<b>A10BJ Glucagon-Like Peptide-1 (GLP-1) Analogues</b>				
<b>A10BJ01</b>	Exenatide	CRP (-)	Suppression of pro-inflammatory cytokines (63)	(22)
<b>A11 VITAMINS</b>				
<b>A11C Vitamin A and D, Incl. Combinations of the Two</b>				
<b>A11CC Vitamin D and Analogues</b>				
<b>A11CC04</b>	Calcitriol	Creatinine (+)	Inhibition of tubular secretion of creatinine in renal osteodystrophy patients (9)	(23,24)
<b>A11CC05</b>	Cholecalciferol	Uric Acid (-)	Increased renal and intestinal clearance (42)	(25)
<b>A11G Ascorbic Acid (Vitamin C), Incl. Combinations</b>				
<b>A11GA Ascorbic Acid (Vitamin C), Plain</b>				
		Total cholesterol (-)	Negative interaction with Trinder's reaction ( <i>in vitro</i> )	(26)
		Triglycerides (-)	Negative interaction with Trinder's reaction ( <i>in vitro</i> )	(26)
<b>A11GA01</b>	Ascorbic acid	Bilirubin (total) (-)	<i>In vitro</i>	(26)
		Creatinine (+)	Interaction with Jaffe ( <i>in vitro</i> )	(26)
		Uric Acid (-)	Negative interaction with Trinder's reaction ( <i>in vitro</i> )	(26,27)
<b>B Blood and Blood Forming Organs</b>				
<b>B01 Antithrombotic Agents</b>				
<b>B01AA Vitamin K Antagonists</b>				

<b>B01AA01</b>	Dicoumarol	Uric Acid (-)	Increased renal clearance (4)	(28)
		Bilirubin (total) (-)	ND (14)	(29)
<b>B01AA03</b>	Warfarin	Uric Acid (+)	Enhanced uric acid production (99)	(30)
		CRP (-)	ND (50)	(31)
<b>B01AC Platelet Aggregation Inhibitors Excl. Heparin</b>				
<b>B01AC04</b>	Clopidogrel	CRP (-)	ND (94)	(32)
<b>B01AC24</b>	Ticagrelor	Uric Acid (+)	Increased uric acid synthesis by xanthine oxidase, reduced renal clearance (233)	(33,34)
<b>B01AE Direct Thrombin Inhibitors</b>				
<b>B01AE07</b>	Dabigatran	CRP (-)	ND (50)	(31)
<b>B02 Antihemorrhagics</b>				
<b>B02B Vitamin K and Other Hemostatics</b>				
<b>B02BX Other Systemic Hemostatics</b>				
		Total Cholesterol (-)	Negative interaction with Trinder's reaction (10)	(35)
		Triglycerides (-)	Negative interaction with Trinder's reaction (10)	(35)
<b>B02BX01</b>	Ethamsylate	Creatinine (-)	Negative interaction with Trinder's reaction (10)	(35)
		Uric Acid (-)	Negative interaction with Trinder's reaction (10)	(35)
<b>B03 Antianemic Preparations</b>				
<b>B03B Vitamin B12 and Folic Acid</b>				
<b>B03BB Folic Acid and Derivatives</b>				

<b>B03BB01</b>	Folic acid	Uric Acid (-)	Reduced uric acid production in hypertensive patients (7685)	(36)
<b>B05 Blood Substitutes and Perfusion Solutions</b>				
<b>B05B I.V. Solutions</b>				
<b>B05BA Solutions for Parenteral Nutrition</b>				
<b>B05BA14</b>	Xylitol	Bilirubin (total) (+)	ND (30)	(37,38)
		Uric Acid (+)	Increase in purine degradation (30)	(37,38)
<b>B05C Irrigating Solutions</b>				
<b>B05CX Other Irrigating Solutions</b>				
<b>B05CX02</b>	Sorbitol	Bilirubin (total) (+)	ND (8)	(38)
		Uric Acid (+)	Increase in uric acid production (8)	(38)
<b>C Cardiovascular System</b>				
<b>C01 Cardiac Therapy</b>				
<b>C01B Antiarrhythmics, Class I and III</b>				
<b>C01BA Antiarrhythmics, Class Ia</b>				
<b>C01BA01</b>	Quinidine	Glucose (fasting) (-)	Stimulation of insulin secretion through its ability to mimic the action of glucose on potassium permeability of the beta cell membrane, with subsequent calcium influx (10)	(39)
		Bilirubin (total) (+)	Haemolysis (CR)	(2,40)
<b>C01BA02</b>	Procainamide	Bilirubin (total) (+)	Haemolysis (CR)	(2)
<b>C01BA03</b>	Disopyramide	Glucose (fasting) (-)	ND (CR)	(41)
<b>C01BA Antiarrhythmics, Class Ib</b>				
<b>C01BB01</b>	Lidocaine	Creatinine (+)	Positive interaction with enzymatic and Jaffe's reaction <i>in vitro</i>	(42)

<b>C01BD Antiarrhythmics, Class III</b>				
<b>C01BD01</b>	Amiodarone	HbA1c (+)	ND (10)	(43)
		ALT (+)	Liver injury (5/899)	(7,8)
<b>C01C Cardiac Stimulants Excl. Cardiac Glycosides</b>				
<b>C01CA Adrenergic and Dopaminergic Agents</b>				
<b>C01CA04</b>	Dopamine	Creatinine (-)	Negative interaction with enzymatic and Jaffe's reaction ( <i>in vitro</i> )	(44)
		Uric Acid (+)	Interaction with phosphomolybden method ( <i>in vitro</i> )	(45,46)
<b>C01CA07</b>	Dobutamine	Creatinine (-)	Negative interaction with enzymatic and Jaffe's reaction ( <i>in vitro</i> )	(44)
<b>C02 Antihypertensives</b>				
<b>C02A Antiadrenergic Agents, Centrally Acting</b>				
<b>C02AB</b>	Methyldopa	Triglycerides (+)	Decreased lipoprotein lipase activity (14)	(47)
		HDL (-)	Decreased HDL production (14)	(47)
		Bilirubin (total) (+)	Haemolysis, liver injury (11/899)	(7,48)
<b>C02AC Imidazoline Receptor Agonists</b>				
<b>C02AC06</b>	Rilmenidine	HDL (+)	ND (24)	(49)
		Glucose (fasting) (-)	Improvement in insulin resistance (24)	(49)
<b>C02C Antiadrenergic Agents, Peripherally Acting</b>				
<b>C02CA Alpha-Adrenoreceptor Antagonists</b>				
<b>C02CA01</b>	Prazosin	Total Cholesterol (-)	ND (12)	(50)
		Triglycerides (-)	Activation of lipoprotein lipase (12)	(50)
		LDL (-)	Reduced Apo-B (12)	(50)
		HDL (+)	ND (12)	(50)

		Insulin (fasting) (-)	Improved insulin action (12)	(50)
		Total cholesterol (-)	Reduced cholesterol synthesis (77)	(51)
		Triglycerides (-)	Activation of lipoprotein lipase (83)	(52)
		LDL (-)	Improved LDL receptor activity (77)	(51)
<b>C02CA04</b>	Doxazosin	HDL (+)	Increased synthesis of Apo-AI (83)	(52)
		Glucose (fasting) (-)	Improved insulin action (77)	(51)
		Insulin (fasting) (-)	Improved insulin action (77)	(51)
		Uric Acid (-)	ND (14)	(53)
<b>C02D Arteriolar Smooth Muscle, Agents Acting On</b>				
<b>C02DB Hydrazinophthalazine Derivatives</b>				
<b>C02DB02</b>	Hydralazine	Total Cholesterol (-)	ND (9)	(54)
<b>C03 Diuretics</b>				
<b>C03A Low-Ceiling Diuretics, Thiazides</b>				
<b>C03AA Thiazides, Plain</b>				
		Total Cholesterol (+)	ND (50)	(55-57)
		Triglycerides (+)	ND (50)	(56-58)
		LDL (+)	ND (50)	(55,56,58)
		HDL (-)	ND (28)	(55)
<b>C03AA03</b>	Hydrochlorothiazide	Glucose (fasting) (+)	Hypokalemia, insulin resistance (28)	(55,59)
		Insulin (fasting) (+)	Hypokalemia, increased peripheral insulin resistance (50)	(56)
		Uric Acid (+)	Increased uric acid reabsorption (151)	(55,60)
<b>C03AX Thiazides, Combinations with Other Drugs</b>				
<b>C03AX01</b>	Hydrochlorothiazide and Captopril	Glucose (fasting) (+)	Insulin resistance (100)	(61)
		Uric Acid (+)	Increased uric acid reabsorption (100)	(61)
<b>C03B Low-Ceiling Diuretics, Excl. Thiazides</b>				

<b>C03BA Sulfonamides, Plain</b>				
<b>C03BA11</b>	Indapamide	Glucose (fasting) (+)	Reduced insulin secretion (50)	(62)
		Uric Acid (+)	Decrease in the fractional urate excretion (342)	(62,63)
<b>C03C High-Ceiling Diuretics</b>				
<b>C03CA Sulfonamides, Plain</b>				
<b>C03CA01</b>	Furosemide	Creatinine (-)	Negative interaction with Jaffe's reaction (3)	(64)
		Uric Acid (+)	Decreased renal excretion (6)	(65)
<b>C03D Aldosterone Antagonists and Other Potassium-Sparing Agents</b>				
<b>C03DA Aldosterone antagonists</b>				
<b>C03DA01</b>	Spironolactone	Triglycerides (-)	ND (15)	(66)
		HDL (-)	ND (15)	(66)
		Insulin (fasting) (+)	Impaired glucose tolerance (15)	(66)
		Uric Acid (+/-)	Decreased renal excretion of uric acid (15)	(66,67)
<b>C04 Peripheral Vasodilators</b>				
<b>C04AC Nicotinic Acid and Derivatives</b>				
<b>C04AC01</b>	Nicotinic acid	Total Cholesterol (-)	Decrease in non-HDL lipoprotein fractions (14)	(68)
		Triglycerides (-)	The inhibition of lipolysis in adipose tissue, reduced triglyceride synthesis (14)	(68)



		LDL (-)	Increased hepatocellular Apo-B degradation, reduced secretion of VLDL (14)	(68)
		HDL (+)	Selective increase in Apo-AI, decreased HDL catabolism (8)	(69)
		Lp(a) (-)	Reduced synthesis of Lp(a) (14)	(68)
		Uric Acid (+)	Increased renal reabsorption Decreased renal secretion Increased uric acid synthesis (5)	(70,71)
<b>C07 Beta Blocking Agents</b>				
<b>C07AA Beta Blocking Agents, Non-Selective</b>				
<b>C07AA01</b>	Alprenolol	Uric Acid (+)	Interference with uric acid excretion, effect on the renal circulation (40)	(72)
		Total Cholesterol (+)	ND (23)	(73)
<b>C07AA03</b>	Pindolol	Triglycerides (+)	Delayed clearance of VLDL (23)	(73)
		HDL (+)	Intrinsic sympathomimetic activity (16)	(74)
		Glucose (fasting) (+)	ND (11)	(75)
		Triglycerides (+)	Inhibition of lipoprotein lipase (18)	(47)
		HDL (-)	Decreased HDL production (18)	(47,76-78)
		Glucose (fasting) (+)	Stimulated glycogenolysis (11)	(79)
<b>C07AA05</b>	Propranolol	Insulin (fasting) (+/-)	Reduced clearance of insulin, insulin resistance, suppressed insulin secretion (39)	(79,80)
		HbA1c (+)	ND (38)	(80)
		Uric Acid (+)	Reduced the mean renal clearance of uric acid (23)	(81)

<b>C07AB Beta Blocking Agents, Selective</b>				
<b>C07AB02</b>	Metoprolol	Total Cholesterol (+)	ND(44)	(82)
		Triglycerides (+)	Reduced clearance of VLDL (23)	(73,83)
		HDL (-)	ND (44)	(82,83)
		Glucose (fasting) (+)	Stimulated glycogenolysis (30)	(84,85)
		Insulin (fasting) (+)	Reduced insulin sensitivity (30)	(85)
		HbA1c (+)	ND (30)	(85)
		Uric Acid (+)	ND (30)	(86)
		CRP (-)	Reduction in proinflammatory cytokines (75)	(87)
<b>C07AB03</b>	Atenolol	Total Cholesterol (-)	ND (46)	(88,89)
		Triglycerides (+)	Reduced activity of lipoprotein lipase (29)	(76,90)
		LDL (-)	ND (46)	(88)
		HDL (-)	Decrease in Apo-AI (30)	(52,76,85,90)
		Lp(a) (+)	ND (15)	(91)
		Glucose (fasting) (+)	Decreased blood flow to muscles and reduced insulin-stimulated glucose uptake (29)	(60,90,92)
		Insulin fasting (+)	ND (23)	(92)
		HbA1c (+)	ND (23)	(92)
ALP (+)	ND (162)	(93)		
Uric Acid (+)	Reduced proximal tubular clearance of uric acid (69)	(94)		
CRP (-)	Reduction in proinflammatory cytokines (15)	(91)		

C07AB12	Nebivolol	HDL (+)	ND (15)	(91)
		Insulin (fasting) (-)	ND (15)	(91)
		CRP (-)	Reduction in proinflammatory cytokines (15)	(91)
<b>C07AG Alpha and Beta Blocking Agents</b>				
C07AG02	Carvedilol	Total Cholesterol (-)	Decrease in the activity of HMG Co-A reductase (43)	(88)
		Triglycerides (-)	Reduced VLDL assembly (23)	(92)
		LDL (-)	Upregulation of LDL receptors (43)	(88)
		HDL (+)	ND (23)	(92)
		Glucose (fasting) (-)	Increased blood flow to skeletal muscles, and increased glucose uptake (23)	(92)
		Insulin (fasting) (-)	Improved insulin sensitivity (23)	(92)
		HbA1c (-)	ND (23)	(92)
		ALP (-)	ND 160)	(93)
		CRP (-)	ND (78)	(95)
<b>C08 Calcium Channel Blockers</b>				
<b>C08C Selective Calcium Channel Blockers with Mainly Vascular Effects</b>				
<b>C08CA Dihydropyridine Derivatives</b>				
C08CA01	Amlodipine	Triglycerides (-)	ND (30)	(96)
		HDL (+)	ND (30)	(96)
		HbA1c (-)	ND (30)	(97)
		Uric Acid (-)	Increase in renal excretion (30)	(97)
C08CA02	Felodipine	Uric Acid (-)	Increased renal excretion (10)	(98)
C08CA05	Nifedipine	Triglycerides (+)	Stimulated lipoprotein lipase activity (39)	(99)

		HDL (+)	ND (39)	(99)
		Glucose (fasting) (+)	Drop in insulin-secreting capacity (5)	(100)
<b>C08CA08</b>	Nitrendipine	Uric Acid (-)	Increased renal excretion (15)	(101)
<b>C08D Selective Calcium Channel Blockers with Direct Cardiac Effects</b>				
<b>C08DA Phenylalkylamine Derivatives</b>				
		HDL (+)	The induction of ABCA1 synthesis (45)	(102)
<b>C08DA01</b>	Verapamil	Glucose (fasting) (-)	Improved beta-cell function and survival in diabetic patients (174)	(103)
		Insulin (fasting) (+)	cAMP-dependent increase in insulin exocytosis (11)	(104)
		ALP (+)	Increased bone turnover (20)	(105)
<b>C08DB Benzothiazepine Derivatives</b>				
		LDL (-)	ND (20)	(106)
<b>C08DB01</b>	Diltiazem	HDL (+)	ND (127)	(107)
		Insulin (fasting) (-)	ND (19)	(79)
<b>C09 Agents Acting on The Renin-Angiotensin System</b>				
<b>C09A ACE Inhibitors, Plain</b>				
		HDL (-)	ND (25)	(85)
		Lp(a) (-)	Reductive cleavage of the disulphide bond and rapid clearance from plasma (10)	(108)
<b>C09AA01</b>	Captopril	Glucose (fasting) (-)	Increased peripheral glucose utilization (12)	(109)
		Bilirubin (total) (+)	Liver injury (CR)	(110)
		Uric Acid (-)	Increased renal excretion (13)	(111)

		ALT (+)	Liver injury (CR)	(110)
		AST (+)	Liver injury (CR)	(110)
		GGT (+)	Liver injury (CR)	(110)
		ALP (+)	Liver injury (CR)	(110)
		Total Cholesterol (-)	ND (9)	(112)
		Triglycerides (-)	ND (12)	(113)
		HDL (+)	Increase in Apo-AI (12)	(113)
		Glucose (fasting) (-)	Improved peripheral glucose utilization (153)	(60,112,114)
		Insulin (fasting) (-)	Improved insulin sensitivity (9)	(112)
<b>C09AA02</b>	Enalapril	HbA1c (-)	ND (1874)	(112, 115)
		Bilirubin (total) (+)	Liver injury (CR)	(116)
		Uric Acid (+/-)	ND (124)	(117,118)
		ALT (+)	Liver injury (CR)	(116)
		AST (+)	Liver injury (CR)	(116)
		GGT (+)	Liver injury (CR)	(116)
		ALP (+)	Liver injury (CR)	(116)
		CRP (-)	ND (35)	(119)
		Total Cholesterol (-)	ND (30)	(55)
		LDL (-)	ND (30)	(55)
		HDL (+)	ND (30)	(55)
<b>C09AA03</b>	Lisinopril	Glucose (fasting) (-)	ND (27)	(49)
		Bilirubin (total) (+)	Liver injury (CR)	(120)
		Uric Acid (-)	Reduced tubular reabsorption (62)	(121,122)
		ALT (+)	Liver injury (5/899)	(7,120)

		AST (+)	Liver injury (5/899)	(7,120)
		GGT (+)	Liver injury (5/899)	(7,120)
		ALP (+)	Liver injury (5/899)	(7,120)
		HDL (+)	Improved cholesterol efflux from lipid-loaded macrophages (30)	(96)
		Bilirubin (+)	Liver injury (3)	(123)
		Uric Acid (-)	Increased fractional excretion (13)	(124)
<b>C09AA05</b>	Ramipril	ALT (+)	Liver injury (3)	(123)
		AST (+)	Liver injury (3)	(123)
		ALP (+)	Liver injury (3)	(123)
		CRP (-)	Reduction of pro-inflammatory cytokines (68)	(125)
		Total Cholesterol (-)	ND (17)	(126)
		LDL (-)	ND (17)	(126)
		Lp(a) (-)	ND (17)	(126)
<b>C09AA09</b>	Fosinopril	Bilirubin (total) (+)	Liver injury (CR)	(127)
		ALT (+)	Liver injury (CR)	(127)
		AST (+)	Liver injury (CR)	(127)
		GGT (+)	Liver injury (CR)	(127)
		ALP (+)	Liver injury (CR)	(127)
<b>C09B ACE Inhibitors, Combinations</b>				
<b>C09BB ACE Inhibitors and Calcium Channel Blockers</b>				
		Triglycerides (-)	ND (41)	(128)
<b>C09BB10</b>	Trandolapril and Verapamil	LDL (-)	ND (41)	(128)
		HDL (+)	ND (100)	(61)
<b>C09C Angiotensin II Receptor Blockers (ARBs), Plain</b>				

<b>C09CA01</b>	Losartan	Uric Acid (-)	Reduced tubular reabsorption (124)	(118,129)
		ALT (+)	Liver injury (2)	(130)
		CRP (-)	Decrease in pro-inflammatory cytokines (126)	(131)
<b>C09CA03</b>	Valsartan	Insulin (fasting) (-)	Improved insulin sensitivity (20)	(132)
		CRP (-)	Decrease in pro-inflammatory cytokines (4202)	(133)
<b>C04CA04</b>	Irbesartan	Uric Acid (-)	Reduced tubular reabsorption (107)	(134)
		Bilirubin (total) (+)	Liver injury (1/899)	(7)
		ALP (+)	Liver injury (1/899)	(7)
		CRP (-)	Decrease in pro-inflammatory cytokines (21)	(135)
<b>C09CA06</b>	Candesartan	HDL (+/-)	ND (31)	(96,136)
		CRP (-)	Decrease in pro-inflammatory cytokines (143)	(135)
<b>C09CA07</b>	Telmisartan	Total Cholesterol (-)	Partial PPAR $\gamma$ agonist action (35)	(137)
		Triglycerides (-)	Partial PPAR $\gamma$ agonist action (35)	(137)
		LDL (-)	Partial PPAR $\gamma$ agonist action (35)	(137)
		HDL (+)	Improved cholesterol removal by ABCB1 (35)	(137)
		HbA1c (-)	Improved insulin sensitivity (35)	(137)
		CRP (-)	ND (35)	(119,137,138)
<b>C09CA08</b>	Olmesartan	HDL (+)	Partial PPAR $\gamma$ agonist action (36)	(139)
		HbA1c (-)	Improved insulin sensitivity (36)	(139)
		CRP (-)	Reduction in pro-inflammatory cytokines (96)	(140)

<b>C09D Angiotensin II Receptor Blockers (ARBs), Combinations</b>				
<b>C09DA Angiotensin II Receptor Blockers (ARBs) and Diuretics</b>				
<b>C09DA01</b>	Losartan and Hydrochlorothiazide	Uric Acid (+/-)	ND (164)	(141,142)
<b>C09DA04</b>	Irbesartan and Hydrochlorothiazide	Uric Acid (+)	ND (449)	(143)
<b>C09DB Angiotensin II Receptor Blockers (ARBs) and Calcium Channel Blockers</b>				
<b>C09DB05</b>	Irbesartan and Amlodipine	LDL (-)	ND (68)	(144)
		HDL (+)	ND (68)	(144)
		Uric Acid (-)	Reduced tubular reabsorption (68)	(144)
<b>C09DB06</b>	Losartan and Amlodipine	Uric Acid (-)	Reduced uric acid production and tubular reabsorption (30)	(141)
<b>C10 Lipid Modifying Agents</b>				
<b>C10A Lipid Modifying Agents, Plain</b>				
<b>C10AA HMG CoA Reductase Inhibitors</b>				
<b>C10AA01</b>	Simvastatin	Triglycerides (-)	Increased lipoprotein lipase activity (151)	(145,146)
		HDL (+)	Inhibition of cholesteryl ester transfer protein (151)	(146)
		Glucose (fasting) (+)	Impaired insulin secretion, impaired glucose uptake in the cells (46,773)	(147)
		Insulin (fasting) (+)	Insulin resistance (153)	(148)
		Creatinine (-)	Increased renal excretion (103)	(149,150)
		Uric Acid (-)	Increased renal excretion (153)	(148,151)
		CRP (-)	Reduction of interleukin-6 (90)	(13,145)



<b>C10AA02</b>	Lovastatin	LP(a)	Decreased synthesis of Apo-B-enriched particles (18)	(152)
		CRP (-)	Reduction in pro-inflammatory cytokines (34)	(153)
<b>C10AA03</b>	Pravastatin	HDL (+)	Inhibition of cholesteryl ester transfer protein (93)	(154)
		Lp(a) (+)	ND (90)	(155)
		HbA1C (+)	ND (93)	(154)
		CRP (-)	Reduction in pro-inflammatory cytokines (865)	(156)
<b>C10AA04</b>	Fluvastatin	Lp(a) (-)	ND (15)	(157)
<b>C10AA05</b>	Atorvastatin	Triglycerides (-)	Increased lipoprotein lipase activity (90)	(145,158,159)
		HDL (+)	Inhibition of cholesteryl ester transfer protein (94)	(154)
		Lp(a) (+/-)	ND (1151)	(160,161)
		Glucose (fasting) (+)	Impaired insulin secretion, impaired glucose uptake in the cells (61,157)	(147,162)
		Insulin (fasting) (+)	Increased insulin resistance (76)	(163)
		HbA1c (+/-)	ND (80)	(154,164)
		Bilirubin (total) (+)	ND (44)	(165)
		Uric Acid (-)	Increased renal excretion (90)	(145,151,166)
		CRP (-)	Reduction in pro-inflammatory cytokines (90)	(145,158,163)
<b>C10AA06</b>	Cerivastatin	CRP (-)	Anti-inflammatory effects (785)	(167)

<b>C10AA07</b>	Rosuvastatin	Triglycerides (-)	Increased lipoprotein lipase activity (60)	(158,159)
		HDL (+)	Inhibition of cholesteryl ester transfer protein (60)	(158)
		Lp(a) (+)	ND (51)	(168)
		Glucose (fasting) (+)	Impaired insulin secretion, impaired glucose uptake by the cells (11,720)	(147)
		Insulin (fasting) (+/-)	ND (153)	(148,159,163)
		HbA1c (-)	ND (80)	(164)
		Uric Acid (-)	Increased renal excretion (153)	(148,166)
		CRP (-)	Reduction in pro-inflammatory cytokines (76)	(163,164)
<b>C10AA08</b>	Pitavastatin	Triglycerides (-)	Increased lipoprotein lipase activity (18,031)	(169)
		HDL (+)	Increase in Apo-AI and ABCB1 expression (18,031)	(169)
		Uric Acid (+)	ND (43)	(166)
		Glucose (fasting) (+)	Impaired insulin secretion, impaired glucose uptake by the cells (8010)	(147)
		CRP (-)	Reduction in pro-inflammatory cytokines (178)	(170)
		Lp(a) (-)	ND (50)	(171)
<b>C10AB Fibrates</b>				
<b>C10AB02</b>	Bezafibrate	Lp(a) (-)	Decreased synthesis of Apo-B-enriched particles (18)	(152)

<b>C10AB04</b>	Gemfibrozil	HDL (+)	Increase in Apo-AI synthesis, reduced expression of cholesterol ester transfer protein (14)	(172)
		Total Cholesterol (-)	Enhanced biliary elimination of cholesterol, increased LDL clearance (14)	(172)
		Lp(a) (-)	Reduced Apo-B100 synthesis (14)	(172)
<b>C10AB05</b>	Fenofibrate	HDL (+)	Increase in Apo-AI synthesis, reduced expression of cholesterol ester transfer protein (26)	(173)
		Lp(a) (+)	Increased production (56)	(174)
		Glucose (fasting) (-)	Increased insulin sensitivity, partial PPAR $\alpha$ agonist activity (31)	(175,176)
		Insulin (fasting) (-)	Increased insulin sensitivity, partial PPAR $\alpha$ agonist activity (31)	(175)
		HbA1c (-)	ND (31)	(175,176)
		Creatinine (+)	Tubular toxicity and increased production of creatinine (3)	(177,178)
		Uric Acid (-)	Reduced tubular reabsorption (4895)	(178,179)
<b>C10AB09</b>	Etofibrate	CRP (-)	Reduction in inflammatory markers (140)	(180)
		Total Cholesterol (-)	Increased LDL removal from plasma (14)	(181)
		HDL (+)	Reduced expression of cholesterol ester transfer protein (14)	(181)
		Lp(a) (-)	Reduced synthesis (14)	(181)

<b>C10AC Bile Acid Sequestrants</b>				
<b>C10AC01</b>	Cholestyramine	Triglycerides (+)	Reduced activation of farnesoid x receptor by bile acids (10)	(182)
<b>C10AC02</b>	Colestipol	Triglycerides (+)	Reduced activation of farnesoid x receptor by bile acids (105)	(183)
<b>C10AX Other Lipid Modifying Agents</b>				
<b>C10AX09</b>	Ezetimibe	Triglycerides (-)	ND (50)	(184)
		Lp(a) (-)	ND (50)	(184)
		HbA1c (-)	ND (50)	(184)
		CRP (-)	ND (50)	(184)
<b>C10AX13</b>	Evolocumab	Lp(a) (-)	Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) (1359)	(185)
<b>C10AX14</b>	Alirocumab	Lp(a) (-)	Inhibition of the proprotein convertase subtilisin/kexin type 9 (PCSK9) (18,924)	(186)
<b>C10B Lipid Modifying Agents, Combinations</b>				
<b>C10BA Combinations of Various Lipid Modifying Agents</b>				
<b>C10BA02</b>	Simvastatin and Ezetimibe	Insulin (fasting) (+)	Insulin resistance (53)	(148)
		Uric Acid (-)	Increased renal excretion (53)	(148)
<b>C10BX Lipid Modifying Agents in Combination with Other Drugs</b>				
<b>C10BX03</b>	Atorvastatin and Amlodipine	Uric Acid (-)	ND (61)	(187)
		CRP (-)	Reduction in inflammation markers (61)	(187)
<b>D Dermatologicals</b>				
<b>D01 Antifungals for Dermatological Use</b>				
<b>D01B Antifungals for Systemic Use</b>				

<b>D01BA02</b>	Terbinafine	ALP (+)	Liver injury (7/899)	(7)
		ALT (+)	Liver injury (7/899)	(7)
<b>D10 Anti-Acne Preparations</b>				
<b>D10B Anti-Acne Preparations for Systemic Use</b>				
<b>D10BA Retinoids for Treatment of Acne</b>				
<b>D10BA01</b>	Isotretinoin	Total Cholesterol (+)	ND (20)	(188,189)
		Triglycerides (+)	ND (20)	(188,189)
		LDL (+)	ND (20)	(188,189)
		HDL (-)	ND (20)	(188)
		ALT (+)	Liver injury (20)	(189)
		AST(+)	Liver injury (20)	(189)
		GGT (+)	Liver injury (246)	(190)
		CRP (+)	ND (246)	(190)
<b>G Genito Urinary System and Sex Hormones</b>				
<b>G03 Sex Hormones and Modulators of The Genital System</b>				
<b>G03A Hormonal Contraceptives for Systemic Use</b>				
<b>G03AA Progestogens and Estrogens, Fixed Combinations</b>				
<b>G03AA12</b>	Drospirenone and Ethinylestradiol	Triglycerides (+)	Increased hepatic production (30)	(191)
		Total Cholesterol (+)	ND (30)	(192)
<b>G03AA15</b>	Chlormadinone and Ethinylestradiol	Triglycerides (+)	Increased secretion of triglyceride-rich lipoproteins (30)	(192)
		LDL (+)	Induced Apo-B synthesis (30)	(192)
		HDL (+)	Increase in Apo-AI (30)	(192)
		Lp(a) (-)	ND (30)	(192)

<b>G03AB Progestogens and Estrogens, Sequential Preparations</b>			
<b>G03AB03</b>	Levonorgestrel and Ethinylestradiol	Total Cholesterol (+)	ND (31) (192)
		Triglycerides (+)	Increased secretion of triglyceride-rich lipoproteins (31) (192)
		LDL (+)	Induced Apo-B synthesis (31) (192)
		HDL (-)	ND (31) (192)
		Lp(a) (-)	ND (31) (192)
<b>G03AB05</b>	Desogestrel and Ethinylestradiol	Total Cholesterol (+)	ND (31) (192,193)
		Triglycerides (+)	Increased secretion of triglyceride-rich lipoproteins (31) (192,193)
		LDL (+)	Induced Apo-B synthesis (31) (192)
		HDL (+)	Increase in Apo-AI (31) (192,193)
<b>G03AC Progestogens</b>			
<b>G03AC06</b>	Medroxyprogesterone	LDL (+)	Inhibition of the delivery of LDL-derived cholesterol to processing enzymes (240) (193)
		HDL (-)	Increased hepatic lipase activity (240) (193)
		Glucose (fasting) (+)	Glucocorticoid-like activity of the drug (240) (194)
		Insulin (fasting) (+)	Increased insulin resistance/ direct stimulation of pancreatic beta-cells (240) (194)
<b>G03AC09</b>	Desogestrel	Total Cholesterol (-)	ND (41) (195)
		Triglycerides (-)	ND (41) (195)
		HDL (-)	Increased hepatic lipase activity (41) (195)
		Lp(a) (-)	ND (41) (195)
<b>G03B Androgens</b>			

<b>G03BA 3-Oxoandrostens (4) Derivatives</b>				
<b>G03BA02</b>	Methyltestosterone	ALP (+)	Liver injury (CR)	(196)
		Uric Acid (+)	Reduced renal excretion of uric acid (160)	(197)
<b>G03BA03</b>	Testosterone	GGT (+)	Liver injury (CR)	
		HDL (-)	ND (14)	(198)
		Lp(a) (-)	Decreased Apo(a) synthesis (14)	(198)
<b>G03C Estrogens</b>				
<b>G03CA Natural and Semisynthetic Estrogens, Plain</b>				
		HDL (+)	Increased production of Apo-AI (11)	(199)
<b>G03CA03</b>	Estradiol	LDL (-)	Stimulation of LDL receptors synthesis, accelerated conversion of cholesterol to bile acids (27)	(200)
		Lp(a) (-)	Reduced Apo(a) production (11)	(201)
		Total cholesterol (-)	ND (14)	(202)
		Triglycerides (+)	Reduced clearance (14)	(202)
		LDL (-)	Increased expression of the LDL receptor (14)	(202)
<b>G03CA57</b>	Conjugated Estrogens	HDL (+)	Increase in the production rate of Apo-AI (14)	(202)
		Lp(a) (-)	Reduced production (14)	(202)
		ALP (-)	Decrease in bone turnover and the loss of remodelling sites (15)	(203)
<b>G03CX Other Estrogens</b>				
<b>G03CX01</b>	Tibolone	Total cholesterol (-)	ND (27)	(204,205)

		Triglycerides (-)	Decreased VLDL synthesis (27)	(204,205)
		HDL (-)	Increased hepatic lipase activity (27)	(204,205)
		HbA1c (-)	The result of the estrogenic effect of tibolone on liver metabolism (5)	(205)
		Lp(a) (-)	Reduced hepatic output of Apo(a) (27)	(204)
		CRP (+)	ND (51)	(206)
<b>G03F Progestogens and Estrogens in Combination</b>				
<b>G03FA Progestogens and Estrogens, Fixed Combinations</b>				
		Total Cholesterol (-)	ND (13)	(207)
		Triglycerides (+)	ND (96)	(208)
		LDL (-)	ND (13)	(207)
<b>G03FA12</b>	Medroxyprogesterone and Estrogen	HDL (+)	ND (96)	(207,208)
		Lp(a) (-)	Reduced hepatic output of Apo(a) (1380)	(209)
		CRP (+)	Elevation of inflammatory markers (28)	(210)
<b>G03FB Progestogens and Estrogens, Sequential Preparations</b>				
		Total Cholesterol (-)	ND (41)	(195)
<b>G03FB09</b>	Levonorgestrel	Triglycerides (-)	ND (41)	(195)
		HDL (-)	Increased hepatic lipase activity (41)	(195)
		Lp(a) (-)	ND (41)	(195)
<b>G03X Other Sex Hormones and Modulators of the Genital System</b>				
<b>G03XA Antigonadotropins and Similar Agents</b>				
<b>G03XA01</b>	Danazol	LDL (+)	Increased synthesis of Apo-B100, inhibition of LDL receptors (37)	(211)



		HDL (-)	Decreased synthesis of Apo-AI, decrease of the activity of the lecithin cholesterol acyltransferase (37)	(211)
<b>G03XC Selective Estrogen Receptor Modulators</b>				
		Total Cholesterol (-)	ND (35)	(212)
		LDL (-)	Stimulation of LDL receptors (35)	(212-214)
<b>G03XC01</b>	Raloxifene	HDL (+)	ND (35)	(212)
		Lp(a) (-)	Reduced Apo(a) synthesis (196)	(208)
		CRP (-)	ND (51)	(206)
<b>G04 Urologicals</b>				
<b>G04C Drugs Used in Benign Prostatic Hypertrophy</b>				
<b>G04CA Alpha-Adrenoreceptor Antagonists</b>				
		Total Cholesterol (-)	Suppression HMG Co-A reductase (26)	(89)
<b>G04CA03</b>	Terazosin	Triglycerides (-)	Reduced VLDL assembly (26)	(89)
		LDL (-)	Reduced Apo-B synthesis (26)	(89)
		HDL (+)	ND (26)	(89)
<b>G04CB Testosterone-5-Alpha Reductase Inhibitors</b>				
<b>G04CB01</b>	Finasteride	HDL (+)	Inhibition of hepatic lipase (13)	(215)
		Lp(a) (+)	ND (13)	(215)
<b>H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins</b>				
<b>H01 Pituitary and Hypothalamic Hormones and Analogues</b>				
<b>H01A Anterior Pituitary Lobe Hormones and Analogues</b>				
<b>H01AC Somatropin and Somatropin Agonists</b>				
<b>H01AC01</b>	Somatropin	Total cholesterol (-)	ND (9)	(216,217)
		Triglycerides (+)	Increased VLDL assembly (9)	(217)

		LDL (-)	Increased turnover, upregulation of LDL receptors (9)	(216,217)
		HDL (+)	ND (9)	(216,217)
		Lp(a) (+)	Stimulation of the synthesis (9)	(216,217)
<b>H02 Corticosteroids for Systemic Use</b>				
<b>H02A Corticosteroids for Systemic Use, Plain</b>				
<b>H02AB Glucocorticoids</b>				
		HDL (+)	Decreased cholesterol ester transfer protein expression and increased secretion of Apo-AI (9)	(218)
<b>H02AB02</b>	Dexamethasone	Glucose (fasting) (+)	Promoted glucose production in the liver and reduced insulin sensitivity (61)	(219,220)
		Insulin (fasting) (+)	Insulin resistance (10)	(220)
<b>H02AB04</b>	Methylprednisolone	Glucose (fasting) (+)	Diabetogenic effect (62)	(221)
		Uric Acid (+)	Elevation of uric acid as a natural scavenger of peroxynitrite (25)	(222)
<b>H02AB06</b>	Prednisolone	Glucose (fasting) (+)	Impaired insulin-mediated glucose uptake (7)	(223)
		Insulin (fasting) (+)	Decreased insulin sensitivity (7)	(223)
		Uric Acid (-)	Increased renal excretion (28)	(224)
<b>H03 Thyroid Therapy</b>				
<b>H03A Thyroid Preparations</b>				
<b>H03AA Thyroid Hormones</b>				
<b>H03AA01</b>	Levothyroxine	Total Cholesterol (-)	ND (100)	(225)
		Triglycerides (-)	Improved VLDL turnover and catabolism of triglycerides (100)	(225)

		LDL (-)	Upregulation of LDL receptors (100)	(225)
		HDL (+)	Reduced hepatic lipase activity (100)	(225)
		Glucose (fasting) (-)	Enhanced glucose clearance (100)	(225)
		Insulin (fasting) (-)	Improved insulin sensitivity (100)	(225)
		HbA1c (-)	ND (100)	(225)
<b>H05 Calcium Homeostasis</b>				
<b>H05A Parathyroid Hormones and Analogues</b>				
<b>H05AA02</b>	Teriparatide	Uric Acid (+)	ND (541)	(226)
<b>H05B Anti-Parathyroid Agents</b>				
<b>H05BA Calcitonin Preparations</b>				
<b>H05BA01</b>	Calcitonin	Uric Acid (-)	Increased renal excretion (9)	(227)
<b>J Antiinfectives for Systemic Use</b>				
<b>J01 Antibacterials for Systemic Use</b>				
<b>J01C Beta-Lactam Antibacterials, Penicillins</b>				
<b>J01CA Penicillins with Extended Spectrum</b>				
<b>J01CA09</b>	Azlocillin	Uric Acid (-)	Inhibition of tubular reabsorption (23)	(228)
<b>J01CE Beta-Lactamase Sensitive Penicillins</b>				
<b>J01CE01</b>	Benzylpenicillin	Bilirubin (total) (+)	Haemolysis (CR)	(229)
		Uric Acid (high dose) (-)	ND (15)	(228)
<b>J01CG Beta-Lactamase Inhibitors</b>				
<b>J01CG01</b>	Sulbactam	Bilirubin (total) (+)	Haemolysis (CR)	(2,230)
<b>J01CR Combinations of Penicillins, Incl. Beta-Lactamase Inhibitors</b>				
<b>J01CR02</b>	Amoxicillin Clavulanate	Bilirubin (total) (+)	Liver injury (208)	(2,231)
		ALT (+)	Liver injury (91/899)	(7,232)
		ALP (+)	Liver injury (91/899)	(7,232)

<b>J01D Other Beta-Lactam Antibacterials</b>				
<b>J01DB First-Generation Cephalosporins</b>				
<b>J01DB03</b>	Cefalotin	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(233)
<b>J01DB04</b>	Cefazolin	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(233)
<b>J01DC Second-Generation Cephalosporins</b>				
<b>J01DC01</b>	Cefoxitin	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(5)
<b>J01DD Third-Generation Cephalosporins</b>				
<b>J01DD04</b>	Ceftriaxone	Bilirubin (total) (+)	Competitive binding to albumin (17)	(234)
<b>J01DE Fourth-Generation Cephalosporins</b>				
<b>J01DE02</b>	Cefpirome	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(233)
<b>J01E Sulfonamides and Trimethoprim</b>				
<b>J01EE Combinations of Sulfonamides and Trimethoprim, Incl. Derivatives</b>				
<b>J01EE01</b>	Sulfamethoxazole and Trimethoprim	Glucose (fasting) (-)	Increased insulin secretion (CR)	(235-237)
		HbA1c (-)	Haemolysis (CR)	(238)
		Bilirubin (total) (+)	Liver injury (31/899)	(7)
		Creatinine (+)	Inhibited tubular secretion (2)	(5)
		Uric Acid (-)	Increased renal excretion (45)	(239)
		ALP (+)	Liver injury (31/899)	(7)
<b>J01F Macrolides, Lincosamides and Streptogramins</b>				
<b>J01FA Macrolides</b>				
<b>J01FA01</b>	Erythromycin	Bilirubin (total) (+)	Liver injury (2/899)	(7)
		ALP (+)	Liver injury (2/899)	(7)

<b>J01FA10</b>	Azithromycin	Bilirubin (total) (+)	Liver injury (18)	(240)
		ALT (+)	Liver injury (18)	(240)
		AST (+)	Liver injury (18)	(240)
		ALP (+)	Liver injury (18)	(240)
<b>J01FF Lincosamides</b>				
<b>J01FF01</b>	Clindamycin	Bilirubin (total) (+)	Liver injury (2/899)	(7)
		ALP (+)	Liver injury (2/899)	(7)
<b>J01FG Streptogramins</b>				
<b>J01GA01</b>	Streptomycin	Creatinine (+)	Positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(241)
<b>J01M Quinolone Antibacterials</b>				
<b>J01MA Fluoroquinolones</b>				
<b>J01MA02</b>	Ciprofloxacin	Glucose (fasting) (+/-)	Increased insulin secretion and unknown mechanisms (688/10,871)	(242)
		ALT (+)	Liver injury (16/899)	(7)
		ALP (+)	Liver injury (16/899)	(7)
<b>J01MA12</b>	Levofloxacin	Glucose (fasting) (+)	ND (820/10,871)	(242)
		ALT (+)	Liver injury (13/899)	(7)
		ALP (+)	Liver injury (13/899)	(7)
<b>J01MA14</b>	Moxifloxacin	Glucose (fasting) (+/-)	Increased insulin secretion and unknown mechanisms (134/10,871)	(242)
<b>J01MA16</b>	Gatifloxacin	Glucose (fasting) (+/-)	Increased insulin secretion and unknown mechanisms (n=868/10,871)	(242)
<b>J01X Other Antibacterials</b>				
<b>J01XE Nitrofurans Derivatives</b>				
<b>J01XE01</b>	Nitrofurantoin	ALT (+)	Liver injury (42/899)	(7)

		ALP (+)	Liver injury (42/899)	(7)
<b>J02 Antimycotics for Systemic Use</b>				
<b>J02AB Imidazole Derivatives</b>				
<b>J02AB02</b>	Ketoconazole	ALT (+)	Liver injury (1/899)	(7)
<b>J02AX Other Antimycotics for Systemic Use</b>				
<b>J02AX01</b>	Flucytosine	Creatinine (+)	Positive interaction with enzymatic reaction (CR)	(243)
<b>J04 Antimycobacterials</b>				
<b>J04A Drugs for Treatment of Tuberculosis</b>				
<b>J04AB Antibiotics</b>				
		Glucose (fasting) (+)	Rifampicin augments intestinal absorption of glucose (69)	(244)
<b>J04AB02</b>	Rifampicin	Bilirubin (total) (+)	Liver injury (15)	(245)
		Uric Acid (+)	Decreased renal excretion (16)	(246)
		ALT (+)	Liver injury (2/899)	(7)
		AST (+)	Liver injury (2/899)	(7)
		<b>J04AC Hydrazides</b>		
<b>J04AC01</b>	Isoniazid	Bilirubin (total) (+)	Liver injury (48/899)	(7,247)
		Uric Acid (+)	Decreased renal excretion (16)	
		ALT (+)	Liver injury (48/899)	(7,247)
		AST (+)	Liver injury (48/899)	(7,247)
<b>J04AK Other Drugs for Treatment of Tuberculosis</b>				
<b>J04AK01</b>	Pyrazinamide	ALT (+)	Liver injury (2/899)	(7)
		Uric Acid (+)	Increased renal reabsorption (216)	(248,249)
<b>J04AK02</b>	Ethambutol	Uric Acid (+)	Decreased renal excretion (14)	(250)
<b>J04AM Combinations of Drugs for Treatment of Tuberculosis</b>				

<b>J04AM05</b>	Rifampicin, Pyrazinamide and Isoniazid	Uric Acid (+)	Decreased renal excretion (16)	(246)
<b>J04B Drugs for Treatment of Lepra</b>				
<b>J04BA02</b>	Dapsone	HbA1c (-)	Increase in methaemoglobin levels and decreased erythrocyte survival (CR)	(251)
<b>J05 Antivirals for Systemic Use</b>				
<b>J05A Direct Acting Antivirals</b>				
<b>J05AE Protease Inhibitors</b>				
<b>J05AE02</b>	Indinavir	Triglycerides (+)	ND (19)	(252)
		Total Cholesterol (+)	ND (20)	(253)
		Triglycerides (+)	Increase in VLDL production (19)	(252)
<b>J05AE03</b>	Ritonavir	LDL (+)	ND (20)	(253)
		HDL (-)	Reduced cholesterol efflux (20)	(253)
		Insulin (fasting) (+)	Induced insulin resistance (8)	(254)
<b>J05AE04</b>	Nelfinavir	Triglycerides (+)	ND (19)	(252)
<b>J05AP Antivirals for Treatment of HCV Infections</b>				
<b>J05AP01</b>	Ribavirin	Bilirubin (total) (+)	Haemolysis (245)	(255)
		HbA1c (-)	Reduced erythrocyte lifespan (CR)	(256)
		Total Cholesterol (+)	ND (24)	(257)
<b>J05AP..</b>	Dasabuvir, Ombitasvir, Paritaprevir, Ritonavir and Ribavirin	Triglycerides (+)	Increase in VLDL production (24)	(257)
		LDL (+)	ND (24)	(257)
		HbA1c (-)	Reduced erythrocyte lifespan (24)	(257)
<b>J05AR Antivirals for Treatment of HIV Infections, Combinations</b>				
<b>J05AR10</b>	Lopinavir and Ritonavir	Total Cholesterol (+)	ND (58)	(258)
		Triglycerides (+)	Increase in VLDL production (58)	(258,259)
<b>J05AR23</b>	Atazanavir and Ritonavir	Total Cholesterol (+)	ND (24)	(260)

		Triglycerides (+)	ND (24)	(260)
		LDL (+)	ND (24)	(260)
		HDL (-)	ND (24)	(260)
		Bilirubin (total) (+)	ND (24)	(260)
<b>J05AR26</b>	Darunavir and Ritonavir	Total Cholesterol (+)	ND (24)	(260)
		Triglycerides (+)	ND (24)	(260)
		LDL (+)	ND (24)	(260)
		HDL (-)	ND (24)	(260)
		Bilirubin (total) (+)	ND (24)	(260)
<b>L Antineoplastic and Immunomodulating Agents</b>				
<b>L01 Antineoplastic Agents</b>				
<b>L01B Antimetabolites</b>				
<b>L01BC Pyrimidine Analogues</b>				
<b>L01BC05</b>	Gemcitabine	Bilirubin (total) (+)	Haemolysis (CR)	(261)
<b>L01C Plant Alkaloids and Other Natural Products</b>				
<b>L01CB Podophyllotoxin Derivatives</b>				
<b>L01CB01</b>	Etoposide	Uric Acid (+)	Interaction with phosphotungstate method (CR)	(262)
<b>L01CE Topoisomerase 1 (TOP1) Inhibitors</b>				
<b>L01CE02</b>	Irinotecan	Bilirubin (total) (+)	Metabolically conjugated by UGT1A1 (CR)	(263)
<b>L01D Cytotoxic Antibiotics and Related Substances</b>				
<b>L01DC Other Cytotoxic Antibiotics</b>				
<b>L01DC01</b>	Bleomycin	Bilirubin (total) (+)	Haemolysis (CR)	(261)
<b>L01DC03</b>	Mitomycin	Bilirubin (total) (+)	Haemolysis (CR)	(261)
<b>L01X Other Antineoplastic Agents</b>				



<b>L01XA Platinum Compounds</b>				
<b>L01XA01</b>	Cisplatin	Bilirubin (total) (+)	Haemolysis (CR)	(261,264)
<b>L01XA02</b>	Carboplatin	Bilirubin (total) (+)	Haemolysis (CR)	(265)
<b>L01XA03</b>	Oxaliplatin	Bilirubin (total) (+)	Haemolysis (CR)	(266)
<b>L01XX Other Antineoplastic Agents</b>				
<b>L01XX02</b>	Asparaginase	Glucose (fasting) (+)	Depletion of asparagine resulting in a decline of insulin production (CR)	(267)
<b>L01XX23</b>	Mitotane	Uric Acid (-)	Increased renal excretion (8)	(268)
<b>L02 Endocrine Therapy</b>				
<b>L02A Hormones and Related Agents</b>				
<b>L02AE Gonadotropin Releasing Hormone Analogues</b>				
<b>L02AE02</b>	Leuprorelin	LDL (+)	ND (21)	(269)
		Bilirubin (+)	ND (21)	(264)
<b>L02AE04</b>	Triptorelin	Total Cholesterol (+)	ND (59)	(270)
		HDL (+)	ND (59)	(270)
		ALP (+)	Increased bone turnover (59)	(270)
<b>L02B Hormone Antagonists and Related Agents</b>				
<b>L02BA Anti-Estrogens</b>				
<b>L02BA01</b>	Tamoxifen	Total Cholesterol (-)	ND (70)	(271,272)
		Triglycerides (+)	Reduced activity of lipoprotein lipase (34)	(272,273)
		LDL (-)	Up-regulation of LDL receptors (70)	(271,272)
		Lp(a) (-)	Altered biosynthesis (8)	(274)
		CRP (-)	Decrease in pro-inflammatory cytokines (67)	(275)
<b>L02BA02</b>	Toremifene	Total Cholesterol (-)	ND (123)	(272,276)

		Triglycerides (-)	ND (34)	(272)
		LDL (-)	Up-regulation of LDL receptors (123)	(272,276)
		HDL (+)	ND (123)	(272,276)
		Lp(a) (-)	Altered biosynthesis (34)	(272)
<b>L02BB Anti-Androgens</b>				
		Total Cholesterol (-)	ND (17)	(277)
		Triglycerides (-)	ND (17)	(277)
		LDL (-)	ND (17)	(277)
<b>L02BB01</b>	Flutamide	Bilirubin (total) (+)	Liver injury (2/1091)	(278)
		ALT (+)	Liver injury (4/1091)	(278)
		AST (+)	Liver injury (4/1091)	(278)
		GGT	Liver injury (4/1091)	(278)
		ALP (+)	Liver injury (1/1091)	(278)
<b>L03 Immunostimulants</b>				
<b>L03AB Interferons</b>				
		Total Cholesterol (+)	ND (152)	(279)
<b>L03AB01</b>	Alpha Interferon	Triglycerides (+)	Stimulation of hepatic lipogenesis, inhibition of lipoprotein lipase by interferon (152)	(279)
<b>L03AX Other Immunostimulants</b>				
<b>L03AX13</b>	Glatiramer Acetate	Uric Acid (+)	Decrease in the amount of uric acid directly degraded by leukocyte (10)	(280)
<b>L04 Immunosuppressants</b>				
<b>L04AA Selective Immunosuppressants</b>				

<b>L04AA10</b>	Sirolimus	Glucose (fasting) (+)	Impaired insulin-mediated suppression of hepatic glucose production, insulin resistance from ectopic triglyceride deposition or direct beta-cell toxicity (5)	(281)
<b>L04AA13</b>	Leflunomide	Uric Acid (-)	Regulation of urate handling in proximal tubules (38)	(282)
<b>L04AD Calcineurin Inhibitors</b>				
<b>L04AD01</b>	Cyclosporine	Total Cholesterol (+)	Inhibition of bile acid synthesis (72)	(283)
		LDL (+)	Increased production (72)	(283)
		Uric Acid (+)	Increased renal reabsorption (104)	(284)
<b>L04AD02</b>	Tacrolimus	Total Cholesterol (-)	ND (27)	(285)
		LDL (-)	ND (27)	(285)
		Uric Acid (+)	ND (47)	(286)
<b>L04AX Other Immunosuppressants</b>				
<b>L04AX01</b>	Azathioprine	Bilirubin (total) (+)	Liver injury (10/899)	(7)
		Uric Acid (-)	Suppressed <i>de novo</i> purine synthesis (2)	(287)
		ALP (+)	Liver injury (10/899)	(7)
<b>L04AX03</b>	Methotrexate	Uric Acid (-)	Changes in adenosine levels (49)	(288)
		ALT (+)	Liver injury (3/899)	(7)
<b>M Musculo-Skeletal System</b>				
<b>M01 Antiinflammatory and Antirheumatic Products</b>				
<b>M01A Antiinflammatory and Antirheumatic Products, Non-Steroids</b>				
<b>M01AB Acetic Acid Derivatives and Related Substances</b>				
<b>M01AB01</b>	Indomethacin	Glucose (fasting) (-)	ND (6)	(289,290)
<b>M01AB05</b>	Diclofenac	Bilirubin (total) (+)	Haemolysis (CR)	(291)

<b>M01AH Coxibs</b>				
<b>M01AH01</b>	Celecoxib	CRP (-)	Reduction in pro-inflammatory cytokines (23)	(292)
<b>M01AH02</b>	Rofecoxib	CRP (-)	Reduction in pro-inflammatory cytokines (18)	(293)
<b>M04 Antigout Preparations</b>				
<b>M04AA Preparations Inhibiting Uric Acid Production</b>				
<b>M04AA01</b>	Allopurinol	ALP (+)	Liver injury (CR)	(294,295)
		ALT (+)	Liver injury (CR)	(295)
		Bilirubin (total) (+)	Liver injury (CR)	(295)
<b>N Nervous System</b>				
<b>N01 Anesthetics</b>				
<b>N01A Anesthetics, General</b>				
<b>N01AB Halogenated Hydrocarbons</b>				
<b>N01AB06</b>	Isoflurane	Bilirubin (total) (+)	ND (90)	(296)
		ALT (+)	Liver injury (90)	(296)
		AST (+)	ND (90)	(296)
		LDH (+)	ND (90)	(296)
		GGT (+)	ND (90)	(296)
<b>N01AB08</b>	Sevoflurane	Bilirubin (total) (+)	ND (90)	(296)
		ALT (+)	Liver injury (160)	(297)
		AST (+)	ND (160)	(297)
		LDH (+)	ND (30)	(297,298)
		ALP (+)	ND (30)	(297,298)
<b>N01AX Other General Anesthetics</b>				
<b>N01AX10</b>	Propofol	Triglycerides (+)	ND (18)	(299)

		ALT (+)	Liver injury (160)	(297)
		AST (+)	ND (160)	(297)
		LDH (+)	ND (160)	(297)
<b>N02 Analgesics</b>				
<b>N02B Other Analgesics and Antipyretics</b>				
<b>N02BA Salicylic Acid and Derivatives</b>				
		Total Cholesterol (-)	ND (20)	(300)
		Lp(a) (-)	Reduced hepatic production of Lp(a) (25)	(301)
		HbA1c (high dose) (+)	Large doses can lead to acetylation of haemoglobin, leading to falsely elevated HbA1c levels due to interference (7)	(302)
<b>N02BA01</b>	Acetylsalicylic acid	Bilirubin (total) (+/-)	Increase: Haemolysis in glucose-6-phosphatase-deficient subjects (279) Decrease: ND (20)	(300,303)
		Creatinine (+/-)	Negative interaction with enzymatic reaction, positive interaction with Jaffe's reaction ( <i>in vitro</i> ), reduced creatinine clearance (49)	(304,305)
		Uric Acid (-)	Decreased net uric acid reabsorption in proximal tubule (49)	(304)
<b>N02BB Pyrazolones</b>				
<b>N02BB02</b>	Metamizole	Creatinine (+/-)	Negative interaction with enzymatic reaction, positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(305)
<b>N02BE Anilides</b>				

		Glucose (fasting) (+)	Falsely elevated continuous glucose monitor (CGM) sensing (10)	(162,306)
		Creatinine (+/-)	Negative interaction with enzymatic reaction, positive interaction with Jaffe's reaction ( <i>in vitro</i> )	(305)
<b>N02BE01</b>	Acetaminophen	Uric Acid (+)	Interference with phosphotungstate method (3)	(307)
		ALT (+)	Liver injury (202)	(308,309)
		AST (+)	Liver injury (20)	(307,310)
		LDH (+)	Liver injury (20)	(307)
		GGT (+)	Acetaminophen-induced liver injury in subjects consuming alcohol (188)	(310)
<b>N03 Antiepileptics</b>				
<b>N03AA Barbiturates and Derivatives</b>				
		Total Cholesterol (+)	ND (23)	(311)
		LDL (+)	ND (23)	(311)
		HDL (+)	ND (23)	(311)
		Lp(a) (+)	ND (23)	(311)
		Bilirubin (total) (-)	Microsomal induction (18)	(312,313)
<b>N03AA02</b>	Phenobarbital	Uric Acid (+)	ND (60)	(314,315)
		ALT (+)	Microsomal induction (23)	(311,316)
		AST (+)	ND (23)	(311)
		GGT (+)	Microsomal induction (23)	(311,316)
		ALP (+)	<i>In vivo</i> increase (microsomal induction) <i>In vitro</i> inhibition of the reaction with p-nitrophenyl phosphate (23)	(311,317,318)

<b>N03AB Hydantoin Derivatives</b>			
<b>N03AB02</b>	Phenytoin	Glucose (fasting) (+)	Impaired insulin sensitivity (CR) (319)
		Bilirubin (total) (+/-)	Liver injury (12/899), enzyme induction (41) (7,313)
		Uric Acid (-)	ND (8) (315, 320)
		ALT (+)	ND (54) (321)
		AST (+)	ND (54) (321)
		ALP (+)	Liver injury (54) (321)
		GGT (+)	Manifestation of an adaptational proliferation of the smooth endoplasmic reticulum with an induction of the cytochrome P-450 system (54) (321,322)
<b>N03AF Carboxamide Derivatives</b>			
<b>N03AF01</b>	Carbamazepine	Total Cholesterol (+)	ND (28) (323)
		Triglycerides (+)	ND (19) (324)
		LDL (+)	ND (28) (323,324)
		HDL (+)	Increased hepatic synthesis of Apo-AI (28)
		Lp(a) (+)	ND (25) (311)
		Bilirubin (total) (-)	Enzyme induction (38) (313)
		Uric Acid (-)	ND (8) (315,320)
		ALT (+)	ND (56) (321)
		AST (+)	ND (56) (321)
		ALP (+)	ND (56) (321,323)

		GGT (+)	Manifestation of an adaptational proliferation of the smooth endoplasmic reticulum with an induction of the cytochrome P-450 system (56)	(311,321)
<b>N03AF02</b>	Oxcarbazepine	ALP (+)	Increase in bone-turnover (44)	(325)
<b>N03AG Fatty Acid Derivatives</b>				
		Total Cholesterol (-)	ND (52)	(315)
		Triglycerides (+)	ND (52)	(315)
		HDL (-)	ND (52)	(315)
		LDL (-)	ND (52)	(315)
		Lp(a) (+)	ND (24)	(311)
		Glucose (fasting) (-)	ND (52)	(315)
<b>N03AG01</b>	Valproic acid	Insulin (fasting) (+)	Insulin resistance (52)	(315)
		Uric Acid (+)	ND (60)	(314, 315)
		ALT (+)	Mild hepatic dysfunction (28)	(326)
		AST (+)	Mild hepatic dysfunction (28)	(326)
		LDH (+)	Mild hepatic dysfunction (28)	(326)
		GGT (+)	ND (47)	(327)
		ALP (+)	ND (50)	(328)
<b>N03AX Other Antiepileptics</b>				
<b>N03AX11</b>	Topiramate	Uric Acid (+)	Inhibitory effect on specific carbonic anhydrase isoenzymes (53)	(329)
<b>N04 Anti-Parkinson Drugs</b>				
<b>N04B Dopaminergic Agents</b>				
<b>N04BA Dopa and Dopa Derivatives</b>				



<b>N04BA01</b>	Levodopa	Uric Acid (+)	Interference with phosphomolybden method ( <i>in vitro</i> )	(46)
<b>N05 Psycholeptics</b>				
<b>N05A Antipsychotics</b>				
<b>N05AA Phenothiazines with Aliphatic Side-Chain</b>				
<b>N05AA01</b>	Chlorpromazine	Total Cholesterol (+)	ND (39)	(330)
		ALT (+)	Liver injury (14/1502)	(8,247)
		ALP (+)	Liver injury (14/1502)	(8,247)
<b>N05AB Phenothiazines with Piperazine Structure</b>				
<b>N05AB03</b>	Perphenazine	ALT (+)	Liver injury (19)	(331)
		AST (+)	Liver injury (19)	(331)
		GGT (+)	Liver injury (19)	(331)
		CRP (+)	ND (143)	(332)
<b>N05AB10</b>	Perazine	ALT (+)	Liver injury (73)	(331)
		AST (+)	Liver injury (73)	(331)
		ALP (+)	Liver injury (73)	(331)
		GGT (+)	Liver injury (73)	(331)
<b>N05AD Butyrophenone Derivatives</b>				
<b>N05AD01</b>	Haloperidol	Total Cholesterol (+)	ND (52)	(333)
		Triglycerides (+)	ND (52)	(333)
		LDL (+)	ND (52)	(333)
		Glucose (fasting) (+)	Increased insulin resistance (25)	(334)
		ALT (+)	Liver injury (35)	(331)
		AST (+)	Liver injury (35)	(331)
		GGT (+)	Liver injury (35)	(331)
ALP (+)	Liver injury (35)	(331)		

		CRP (+)	ND (36)	(335)
<b>N05AE Indole Derivatives</b>				
<b>N05AE04</b>	Ziprasidone	Total Cholesterol (-)	ND (40)	(336)
		Triglycerides (-)	ND (40)	(336)
		ALT (+)	Liver injury (118)	(337)
		AST (+)	Liver injury (118)	(337)
		CRP (+)	ND (86)	(332)
<b>N05AE05</b>	Lurasidone	Total Cholesterol (+)	ND (50)	(338)
		Triglycerides (-)	ND (50)	(338)
		LDL (-)	ND (50)	(338)
		HDL (-)	ND (50)	(338)
		Glucose (fasting) (+)	ND (50)	(338)
		Insulin (fasting) (+)	ND (50)	(338)
		HbA1c (+)	ND (50)	(338)
<b>N05AF Thioxanthene Derivatives</b>				
<b>N05AF03</b>	Chlorprothixene	Uric Acid (-)	Increased renal excretion (30)	(339,340)
<b>N05AH Diazepines, Oxazepines, Thiazepines and Oxepines</b>				
<b>N05AH02</b>	Clozapine	Total Cholesterol (+)	ND (38)	(334,339,341-343)
		Triglycerides (+)	ND (38)	(341-343)
		Glucose (fasting) (+)	Insulin resistance (38)	(334,341,343)
		ALT (+)	Liver injury (96)	(331)
		AST (+)	Liver injury (96)	(331)
		GGT (+)	Liver injury (96)	(331)
		ALP (+)	Liver injury (96)	(331)
CRP (+)	ND (33)	(343)		

<b>N05AH03</b>	Olanzapine	Total Cholesterol (+)	ND (54)	(333,334,342)
		Triglycerides (+)	ND (54)	(333,338,342)
		LDL (+)	ND (54)	(333,338)
		HDL (-)	ND (51)	(338)
		Glucose (fasting) (+)	ND (51)	(334,338,344)
		Insulin (fasting) (+)	ND (51)	(338)
		HbA1c (+)	ND (51)	(338)
		Bilirubin (total) (+)	Liver injury (33)	(345)
		ALT (+)	Liver injury (33)	(345)
		AST (+)	Liver injury (33)	(345)
		GGT (+)	Liver injury (33)	(345)
		ALP (+)	Liver injury (33)	(345)
		CRP (+)	ND (202)	(332,346)
<b>N05AH04</b>	Quetiapine	Bilirubin (total) (+)	Liver injury (48)	(345)
		ALT (+)	Liver injury (48)	(345)
		AST (+)	Liver injury (48)	(345)
		GGT (+)	Liver injury (48)	(345)
		ALP (+)	Liver injury (48)	(345)
		CRP (+)	ND (180)	(332,347)
<b>N05AL Benzamides</b>				
<b>N05AL05</b>	Amisulpride	CRP (+)	ND (43)	(346)
<b>N05AN Lithium</b>				
<b>N05AN01</b>	Lithium	Uric Acid (-)	Increased renal excretion (98)	(348)
<b>N05AX Other Antipsychotics</b>				
<b>N05AX08</b>	Risperidone	Total Cholesterol (+)	ND (58)	(333)

		Triglycerides (+)	ND (58)	(333,342)
		LDL (+)	ND (58)	(333)
		Glucose (fasting) (+)	ND (50)	(342)
		Bilirubin (total) (+)	Liver injury (29)	(345,349)
		ALT (+)	Liver injury (121)	(337)
		AST (+)	Liver injury (121)	(337)
		GGT (+)	Liver injury (29)	(345,349)
		ALP (+)	Liver injury (29)	(345,349)
		CRP (+)	ND (178)	(332,347)
<b>N05AX11</b>	Zotepine	Uric Acid (-)	Inhibition of reabsorption of uric acid (16)	(350)
		Triglycerides (-)	ND (24)	(351)
		ALT (-)	ND (24)	(351)
<b>N05AX12</b>	Aripiprazole	AST (-)	ND (24)	(351)
		GGT (-)	ND (24)	(351)
		ALP (-)	ND (24)	(351)
		CRP (-/+)	ND (46)	
<b>N06 Psychoanaleptics</b>				
<b>N06A Antidepressants</b>				
<b>N06AA Non-Selective Monoamine Reuptake Inhibitors</b>				
<b>N06AA10</b>	Nortriptyline	CRP (-)	ND (126)	(352)
<b>N06AB Selective Serotonin Reuptake Inhibitors</b>				
		Total Cholesterol (+)	ND (28)	(353)
<b>N06AB03</b>	Fluoxetine	Triglycerides (+)	ND (28)	(353)
		LDL (+)	ND (28)	(353)

		ALT (+)	Liver injury (1/899)	(7)
		CRP (-)	ND (48)	(354)
<b>N06AB05</b>	Paroxetine	Lp(a) (-)	ND (21)	(355)
<b>N06AB06</b>	Sertraline	CRP (-)	ND (47)	(356)
<b>N06AB10</b>	Escitalopram	CRP (-)	ND (115)	(352)
<b>P Antiparasitic Products, Insecticides and Repellents</b>				
<b>P01 Antiprotozoals</b>				
<b>P01B Antimalarials</b>				
<b>P01BD Diaminopyrimidines</b>				
<b>P01BD01</b>	Pyrimethamine	Creatinine (+)	Inhibition of tubular secretion (6)	(305)
<b>R Respiratory System</b>				
<b>R03 Drugs for Obstructive Airway Diseases</b>				
<b>R03A Adrenergics, Inhalants</b>				
<b>R03AC Selective Beta-2-Adrenoreceptor Agonists</b>				
<b>R03AC12</b>	Salmeterol	Glucose (fasting) (+)	ND (16)	(357)
<b>R03AC13</b>	Formoterol	Glucose (fasting) (+)	ND (16)	(357,358)
<b>R03C Adrenergics for Systemic Use</b>				
<b>R03CC Selective Beta-2-Adrenoreceptor Agonists</b>				
<b>R03CC02</b>	Salbutamol	Glucose (fasting) (+)	ND (12)	(358)
<b>R03CC04</b>	Fenoterol	Glucose (fasting) (+)	ND (12)	(358)
<b>R03D Other Systemic Drugs for Obstructive Airway Diseases</b>				
<b>R03DA Xanthines</b>				
<b>R03DA04</b>	Theophylline	Insulin (fasting) (+)	Increase in cAMP level in pancreatic beta-cells (5)	(359)
		Uric Acid (+)	Inhibitory effect on HGPRT-ase (12)	(360)

<b>R06 Antihistamines for Systemic Use</b>				
<b>R06AX Other Antihistamines for Systemic Use</b>				
<b>R06AX02</b>	Cyproheptadine	ALT (+)	Liver injury (CR)	(361)
		ALP (+)	Liver injury (CR)	(361)
<b>V various</b>				
<b>V03 All Other Therapeutic Products</b>				
<b>V03AF Detoxifying Agents for Antineoplastic Treatment</b>				
<b>V03AF07</b>	Rasburicase	Uric Acid (-)	Metabolism of uric acid to allantoin (20)	(362)
<b>V03AX Other therapeutic products</b>				
<b>J03AX03</b>	Cobicistat	Creatinine (+)	Inhibition of tubular secretion (30)	(363)
<b>V06 General Nutrients</b>				
<b>V06DC Carbohydrates</b>				
<b>V06DC02</b>	Fructose	Uric Acid (+)	Increased uric acid production, decreased renal excretion (16)	(364)
<b>ATC Non-Classified</b>				
<b>none</b>	Azelnidipine	Glucose (fasting) (-)	Inhibition of the sympathetic nervous system (17)	(365)
		CRP (-)	Decrease in pro-inflammatory cytokines (17)	(365)
<b>none</b>	Droloxifene	LDL (-)	ND (24)	(366)
		Lp(a) (-)	ND (24)	(366)
<b>none</b>	Lactate	Uric Acid (+)	Decreased the fractional clearance of uric acid (5)	(367)

The drugs are listed according to the Anatomical Therapeutic Chemical Classification (ATC) System. (+) – increased values. (-) – decreased values. ND - not described; CR – case report. ABC - ATP Binding Cassette. ALT - Alanine Aminotransferase. Apo – apolipoprotein. AST - Aspartate Aminotransferase. cAMP - Cyclic adenosine monophosphate. CRP - C-Reactive Protein. HGPRT-ase - Hypoxanthine-guanine phosphoribosyltransferase. HMG Co-A - 3-Hydroxy-3-methylglutaryl-coenzyme A. GGT -

Gamma-Glutamyl Transferase. HbA1c - Hemoglobin A1c. HDL - High Density Lipoprotein. LDH - Lactate Dehydrogenase. LDL - Low Density lipoprotein. Lp(a) - Lipoprotein (a). PPAR - Peroxisome proliferator-activated receptor. TNF- $\alpha$  – Tumor necrosis factor alpha. UGT1A1 - UDP-glucuronosyltransferase 1A1.

## References:

1. ATC classification index with DDDs, 2023. Oslo, Norway 2022 [Available from: [https://www.whocc.no/atc\\_ddd\\_index/](https://www.whocc.no/atc_ddd_index/). Accessed Feb 02<sup>nd</sup> 2023.
2. Ah YM, Kim YM, Kim MJ, Choi YH, Park KH, Son IJ, et al. Drug-induced hyperbilirubinemia and the clinical influencing factors. *Drug Metab Rev.* 2008;40(4):511-37.
3. Choi JH, Ahn BM, Yi J, Lee JH, Lee JH, Nam SW, et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury. *Pharmacogenet Genomics.* 2007;17(6):403-15.
4. Christensen CK, Mogensen CE, Hanberg Sørensen F. Renal function and cimetidine. Urinary albumin and beta 2-microglobulin excretion and creatine clearance during cimetidine treatment. *Scand J Gastroenterol.* 1981;16(1):129-34.
5. Ducharme MP, Smythe M, Strohs G. Drug-induced alterations in serum creatinine concentrations. *Ann Pharmacother.* 1993;27(5):622-33.
6. Yeung CK, Wong KL, Ng MT, Lai CL. Effects of cimetidine, ranitidine, and antacid on renal function. *Clin Ther.* 1984;6(5):620-4.
7. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, et al. Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. *Gastroenterology.* 2015;148(7):1340-52.e7.
8. Navarro VJ, Senior JR. Drug-related hepatotoxicity. *N Engl J Med.* 2006;354(7):731-9.
9. Bateson MC, Maclean D, Evans JR, Bouchier IA. Chenodeoxycholic acid therapy for hypertriglyceridaemia in men. *Br J Clin Pharmacol.* 1978;5(3):249-54.



10. Poupon RE, Ouguerram K, Chrétien Y, Verneau C, Eschwège E, Magot T, et al. Cholesterol-lowering effect of ursodeoxycholic acid in patients with primary biliary cirrhosis. *Hepatology*. 1993;17(4):577-82.
11. Gokcel A, Gumurdulu Y, Karakose H, Melek Ertorer E, Tanaci N, BascilTutuncu N, et al. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. *Diabetes Obes Metab*. 2002;4(1):49-55.
12. Bell DS, Ovalle F. Metformin lowers lipoprotein(a) levels. *Diabetes Care*. 1998;21(11):2028.
13. Bulcão C, Ribeiro-Filho FF, Sañudo A, Roberta Ferreira SG. Effects of simvastatin and metformin on inflammation and insulin resistance in individuals with mild metabolic syndrome. *Am J Cardiovasc Drugs*. 2007;7(3):219-24.
14. Wang J, Zhu L, Hu K, Tang Y, Zeng X, Liu J, et al. Effects of metformin treatment on serum levels of C-reactive protein and interleukin-6 in women with polycystic ovary syndrome: a meta-analysis: A PRISMA-compliant article. *Medicine (Baltimore)*. 2017;96(39):e8183.
15. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. *J Med Invest*. 2006;53(1-2):87-94.
16. Matsumoto K, Miyake S, Yano M, Ueki Y, Tominaga Y. Increase of lipoprotein (a) with troglitazone. *Lancet*. 1997;350(9093):1748-9.
17. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. *Dig Dis Sci*. 2002;47(7):1632-7.
18. Kadoglou NP, Tsanikidis H, Kapelouzou A, Vrabas I, Vitta I, Karayannacos PE, et al. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and

ghrelin levels in patients with type 2 diabetes mellitus. *Metabolism*. 2010;59(3):373-9.

19. Kahn SE, Haffner SM, Viberti G, Herman WH, Lachin JM, Kravitz BG, et al. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care*. 2010;33(1):177-83.

20. Vijay SK, Mishra M, Kumar H, Tripathi K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. *Acta Diabetol*. 2009;46(1):27-33.

21. Satoh-Asahara N, Sasaki Y, Wada H, Tochiya M, Iguchi A, Nakagawachi R, et al. A dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patients. *Metabolism*. 2013;62(3):347-51.

22. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Ragonesi PD, Querci F, et al. Exenatide versus glibenclamide in patients with diabetes. *Diabetes Technol Ther*. 2010;12(3):233-40.

23. Christiansen C, Rødbro P, Christensen MS, Hartnack B, Transbøl I. Deterioration of renal function during treatment of chronic renal failure with 1,25-dihydroxycholecalciferol. *Lancet*. 1978;2(8092 Pt 1):700-3.

24. Andreev E, Koopman M, Arisz L. A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible? *J Int Med*. 1999;246(3):247-52.

25. Nimitphong H, Saetung S, Chailurkit LO, Chanprasertyothin S, Ongphiphadhanakul B. Vitamin D supplementation is associated with serum uric acid concentration in patients with prediabetes and hyperuricemia. *J Clin Transl Endocrinol*. 2021;24:100255.

26. Meng QH, Irwin WC, Fesser J, Massey KL. Interference of ascorbic acid with chemical analytes. *Ann Clin Biochem.* 2005;42(Pt 6):475-7.
27. Bouvier D, Sapin V, Bonnard-Gougeon M, Marceau G. Retinol potentiates the inhibitory effect of ascorbic acid on uric acid assay. *Clin Chem Lab Med.* 2010;48(5):693-5.
28. Hansen OE, Holten C. Uricosuric effect of dicoumarol. *Lancet.* 1958;1(7029):1047-8.
29. Vets E, Rossignol JF, Jackson AS. Effects of nitazoxanide on pharmacokinetics and pharmacodynamics of a single dose of warfarin. *Am J Health Syst Pharm.* 2009;66(9):838-42.
30. Menon RK, Mikhailidis DP, Bell JL, Kernoff PB, Dandona P. Warfarin administration increases uric acid concentrations in plasma. *Clin Chem.* 1986;32(8):1557-9.
31. Amini S, Gholami K, Bakhshandeh H, Fariborz Farsad B. Effect of Oral Anticoagulant Therapy on Coagulation Activity and Inflammatory Markers in Patients with Atrial Fibrillation Undergoing Ablation: A Randomized Comparison between Dabigatran and Warfarin. *Iran J Pharm Res.* 2013;12(4):945-53.
32. Woodward M, Lowe GD, Francis LM, Rumley A, Cobbe SM. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. *J J Thromb Haemost.* 2004;2(11):1934-40.
33. Nardin M, Verdoia M, Pergolini P, Rolla R, Barbieri L, Schaffer A, et al. Serum uric acid levels during dual antiplatelet therapy with ticagrelor or clopidogrel: Results from a single-centre study. *Nutr Metab Cardiovasc Dis.* 2016;26(7):567-74.

34. Zhang N, Zhang Z, Yang Y, Xu Y, Li G, Liu T. Ticagrelor-related gout: An underestimated side effect. *Int J Cardiol.* 2015;192:11-3.
35. Dastych M, Wiewiorka O, Benovská M. Ethamsylate (Dicynone) interference in determination of serum creatinine, uric acid, triglycerides, and cholesterol in assays involving the Trinder reaction; in vivo and in vitro. *Clin Lab.* 2014;60(8):1373-6.
36. Qin X, Li Y, He M, Tang G, Yin D, Liang M, et al. Folic acid therapy reduces serum uric acid in hypertensive patients: a substudy of the China Stroke Primary Prevention Trial (CSPPT). *Am J Clin Nutr.* 2017;105(4):882-9.
37. Korttila K, Mattila MA. Increased serum concentrations of lactic, pyruvic and uric acid and bilibubin after postoperative xylitol infusion. *Acta Anaesthesiol Scand.* 1979;23(3):273-7.
38. Förster H, Meyer E, Ziege M. [Increase of serum uric acid and serum bilirubin following high dose infusions of sorbitol, xylitol and fructose]. *Klin Wochenschr.* 1970;48(14):878-9.
39. Njomatchoua AC, Tankeu AT, Sobngwi E, Mbanya JC. Glycemic effects of quinine infusion in healthy volunteers. *BMC Res Notes.* 2017;10(1):423.
40. Ballas SK, Caro JF, Miguel O. Quinidine-induced hemolytic anemia: immunohematologic characterization. *Transfusion.* 1978;18(2):215-9.
41. Goldberg IJ, Brown LK, Rayfield EJ. Disopyramide (Norpace)-induced hypoglycemia. *Am J Med.* 1980;69(3):463-6.
42. Spinler SA, Anderson BD, Kindwall KE. Lidocaine interference with Ektachem analyzer determinations of serum creatinine concentration. *Clin Pharm.* 1989;8(9):659-63.

43. Lakhdar AA, Farish E, Dunn FG, Hillis WS. Amiodarone therapy and glucose tolerance--a prospective trial. *Eur J Clin Pharmacol.* 1988;34(6):651-2.
44. Saenger AK, Lockwood C, Snozek CL, Milz TC, Karon BS, Scott MG, et al. Catecholamine interference in enzymatic creatinine assays. *Clin Chem.* 2009;55(9):1732-6.
45. Cawein MJ, Hewins J. False rise in serum uric acid after L-dopa. *T N Engl J Med.* 1969;281(26):1489-90.
46. Bierer DW, Quebbemann AJ. Interference of levodopa and its metabolites with colorimetry of uric acid. *Clin Chem.* 1981;27(5):756-8.
47. Leon AS, Agre J, McNally C, Bell C, Neibling M, Grimm R, Jr., et al. Blood lipid effects of antihypertensive therapy: a double-blind comparison of the effects of methyldopa and propranolol. *J Clin Pharmacol.* 1984;24(5-6):209-17.
48. Murphy WG, Kelton JG. Methyldopa-induced autoantibodies against red blood cells. *Blood Rev.* 1988;2(1):36-42.
49. Anichkov DA, Shostak NA, Schastnaya OV. Comparison of rilmenidine and lisinopril on ambulatory blood pressure and plasma lipid and glucose levels in hypertensive women with metabolic syndrome. *Curr Med Res Opin.* 2005;21(1):113-9.
50. Swislocki AL, Hoffman BB, Sheu WH, Chen YD, Reaven GM. Effect of prazosin treatment on carbohydrate and lipoprotein metabolism in patients with hypertension. *Am J Med.* 1989;86(1b):14-8.
51. Lehtonen A. Doxazosin effects on insulin and glucose in hypertensive patients. The Finnish Multicenter Study Group. *Am Heart J.* 1991;121(4 Pt 2):1307-11.

52. Talseth T, Westlie L, Daae L. Doxazosin and atenolol as monotherapy in mild and moderate hypertension: a randomized, parallel study with a three-year follow-up. *Am Heart J.* 1991;121(1 Pt 2):280-5.
53. Huupponen R, Lehtonen A, Vähätalo M. Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. *Eur J Clin Pharmacol.* 1992;43(4):365-8.
54. Bevan EG, Pringle SD, Waller PC, Herrick AL, Findlay JG, Murray GD, et al. Comparison of captopril, hydralazine and nifedipine as third drug in hypertensive patients. *J Hum Hypertens.* 1993;7(1):83-8.
55. Fogari R, Zoppi A, Malamani GD, Marasi G, Vanasia A, Villa G. Effects of different antihypertensive drugs on plasma fibrinogen in hypertensive patients. *Br J Clin Pharmacol.* 1995;39(5):471-6.
56. Pollare T, Lithell H, Berne C. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. *N Engl J Med.* 1989;321(13):868-73.
57. Grimm RH, Jr., Leon AS, Hunninghake DB, Lenz K, Hannan P, Blackburn H. Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. *Ann Intern Med.* 1981;94(1):7-11.
58. Akhtar F, Khalid F, Wang H, Zhang D, Gong X. The Effect of Thiazide Diuretics on Blood Lipid Profile in Hypertensive Adults: A Meta-analysis of Randomized Controlled Trials. *Cureus.* 2018;10(5):e2651.
59. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Jr., et al. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. *Pharmacotherapy.* 2014;34(11):1132-40.

60. Helgeland A, Strømme R, Hagelund CH, Tretli S. Enalapril, atenolol, and hydrochlorothiazide in mild to moderate hypertension. A comparative multicentre study in general practice in Norway. *Lancet*. 1986;1(8486):872-5.
61. Cifková R, Nakov R, Novozámská E, Hejl Z, Petrzílková Z, Poledne R, et al. Evaluation of the effects of fixed combinations of sustained-release verapamil/trandolapril versus captopril/hydrochlorothiazide on metabolic and electrolyte parameters in patients with essential hypertension. *J Hum Hypertens*. 2000;14(6):347-54.
62. Zhang JL, Yu H, Hou YW, Wang K, Bi WS, Zhang L, et al. Impact of long-term potassium supplementation on thiazide diuretic-induced abnormalities of glucose and uric acid metabolisms. *J Hum Hypertens*. 2018;32(4):301-10.
63. Leonetti G, Rappelli A, Salvetti A, Scapellato L. Long-term effects of indapamide: final results of a two-year Italian multicenter study in systemic hypertension. *Am J Cardiol*. 1990;65(17):67h-71h.
64. Murphy JL, Hurt TL, Griswold WR, Peterson BM, Rodarte A, Krous HF, et al. Interference with creatinine concentration measurement by high dose furosemide infusion. *Crit Care Med*. 1989;17(9):889-90.
65. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Hada T. Effect of furosemide on renal excretion of oxypurinol and purine bases. *Metabolism*. 2001;50(2):241-5.
66. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. *Acta Med Scand*. 1983;213(1):27-30.

67. Cabrera SE, Edwards NC, Steeds RP, Townend JN, Ferro CJ. Spironolactone increases serum uric acid levels in patients with chronic kidney disease. *J Hum Hypertens*. 2014;28(3):210-1.
68. Seed M, O'Connor B, Perombelon N, O'Donnell M, Reaveley D, Knight BL. The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. *Atherosclerosis*. 1993;101(1):61-8.
69. King JM, Crouse JR, Terry JG, Morgan TM, Spray BJ, Miller NE. Evaluation of effects of unmodified niacin on fasting and postprandial plasma lipids in normolipidemic men with hypoalphalipoproteinemia. *Am J Med*. 1994;97(4):323-31.
70. Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. *Rheumatology*. 2017;56(5):679-88.
71. Gaut ZN, Pocolinko R, Solomon HM, Thomas GB. Oral glucose tolerance, plasma insulin, and uric acid excretion in man during chronic administration of nicotinic acid. *Metabolism*. 1971;20(11):1031-5.
72. Bengtsson C. Comparison between alprenolol and chlorthalidone as antihypertensive agents. *Acta Med Scand*. 1972;191(5):433-9.
73. Szollár LG, Mészáros I, Tornóci L, Rischák K, Molnár M, Mányai S. Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females. *Cardiovasc Pharmacol*. 1990;15(6):911-7.
74. Pasotti C, Capra A, Fiorella G, Vibelli C, Chierichetti SM. Effects of pindolol and metoprolol on plasma lipids and lipoproteins. *Br J Clin Pharmacol*. 1982;13(Suppl 2):435s-9s.
75. Lehtonen A. The effects of trimazosin and pindolol on serum lipids, blood glucose and serum insulin levels. *Acta Med Scand*. 1985;218(2):213-6.



76. Punda A, Polić S, Rumboldt Z, Bagatin J, Marković V, Lukin A. Effects of atenolol and propranolol on platelet aggregation in moderate essential hypertension: randomized crossover trial. *Croat Med J.* 2005;46(2):219-24.
77. Dujovne CA, DeCoursey S, Krehbiel P, Jackson B, Chernoff S. Serum lipids in normo- and hyperlipidemics after methyldopa and propranolol. *Clin Pharmacol Ther.* 1984;36(2):157-62.
78. Velasco M, Hurt E, Silva H, Urbina-Quintana A, Hernández-Pieretti O, Feldstein E, et al. Effects of prazosin and propranolol on blood lipids and lipoproteins in hypertensive patients. *Am J Med.* 1986;80(2a):109-13.
79. Chellingsworth MC, Kendall MJ, Wright AD, Singh BM, Pasi J. The effects of verapamil, diltiazem, nifedipine and propranolol on metabolic control in hypertensives with non-insulin dependent diabetes mellitus. *J Hum Hypertens.* 1989;3(1):35-9.
80. Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. *Blood Press.* 1992;1(2):92-101.
81. Leren P, Foss PO, Helgeland A, Hjermann I, Holme I, Lund-Larsen PG. Effect of propranolol and prazosin on blood lipids. The Oslo Study. *Lancet.* 1980;2(8184):4-6.
82. Lacourcière Y, Poirier L, Boucher S, Spenard J. Comparative effects of diltiazem sustained-release formulation and metoprolol on ambulatory blood pressure and plasma lipoproteins. *Clin Pharmacol Ther.* 1990;48(3):318-24.
83. Malmqvist K, Kahan T, Isaksson H, Ostergren J. Regression of left ventricular mass with captopril and metoprolol, and the effects on glucose and lipid metabolism. *Blood Press.* 2001;10(2):101-10.

84. Groop L, Tötterman KJ, Harno K, Gordin A. Influence of beta-blocking drugs on glucose metabolism in hypertensive, non-diabetic patients. *Acta Med Scand.* 1983;213(1):9-14.
85. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. *BMJ.* 1989;298(6681):1152-7.
86. Aurell M, Bengtsson C, Björck S. Enalapril versus metoprolol in primary hypertension--effects on the glomerular filtration rate. *Nephrol Dial Transplant.* 1997;12(11):2289-94.
87. King DE, Egan BM, Mainous AG, 3rd, Geesey ME. The effect of extended-release metoprolol succinate on C-reactive protein levels in persons with hypertension. *J Clin Hypertens.* 2006;8(4):257-60.
88. Oh PC, Kang WC, Moon J, Park YM, Kim S, Kim MG, et al. Anti-Anginal and Metabolic Effects of Carvedilol and Atenolol in Patients with Stable Angina Pectoris: A Prospective, Randomized, Parallel, Open-Label Study. *Am J Cardiovasc Drugs.* 2016;16(3):221-8.
89. Bur A, Woisetschläger C, Herkner H, Derhaschnig U, Quehenberger P, Hirschl MM. [Effects of terazosine and atenolol on serum lipids in essential hypertension]. *Z Kardiol.* 2002;91(9):685-92.
90. Pollare T, Lithell H, Mörlin C, Pröntare H, Hvarfner A, Ljunghall S. Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. *J Hypertens.* 1989;7(7):551-9.
91. Rizos E, Bairaktari E, Kostoula A, Hasiotis G, Achimastos A, Ganotakis E, et al. The combination of nebivolol plus pravastatin is associated with a more beneficial

metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study. *J Cardiovasc Pharmacol Ther.* 2003;8(2):127-34.

92. Giugliano D, Acampora R, Marfella R, De Rosa N, Ziccardi P, Ragone R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. *Ann Intern Med.* 1997;126(12):955-9.

93. Ruilope LM. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension. *Am J Hypertens.* 1994;7(2):129-36.

94. Andersen GS. Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives. *Acta Med Scand.* 1985;218(2):165-72.

95. Nessler J, Nessler B, Golebiowska-Wiatrak R, Palka I, Gackowski A, Kitlinski M, et al. Serum biomarkers and clinical outcomes in heart failure patients treated de novo with carvedilol. *Cardiol J.* 2013;20(2):144-51.

96. Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Koh Y, et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. *Int J Cardiol.* 2010;140(1):73-81.

97. Buscemi S, Buscemi C, Borzì AM, Cosentino L, Rosafio G, Randazzo C, et al. Metabolic and Cardiovascular Effects of Switching Thiazides to Amlodipine in Hypertensive Patients With and Without Type 2 Diabetes (the Diuretics and Diabetes Control Study). *Metab Syndr Relat Disord.* 2020;18(2):110-8.

98. Hulthén UL, Katzman PL. Renal effects of acute and long-term treatment with felodipine in essential hypertension. *J Hypertens.* 1988;6(3):231-7.

99. Grosskopf I, Shaish A, Charach G, Harats D, Kamari Y. Nifedipine Treatment for Hypertension is Associated with Enhanced Lipolytic Activity and Accelerated Clearance of Postprandial Lipemia. *Horm Metab Res.* 2016;48(4):257-62.
100. Krempf M, Ranganatan S, Ritz P, Garnier JM, Charbonnel B. Effect of nifedipine on glucose potentiation of the acute insulin response to arginine in non-insulin-dependent diabetics. *Eur J Clin Pharmacol.* 1991;41(5):411-5.
101. Weidmann P, Gnädinger MP, Schohn D, Riesen W, Jahn H. Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure. *Eur J Clin Pharmacol.* 1989;36(3):223-7.
102. Midtbø KA. Effects of long-term verapamil therapy on serum lipids and other metabolic parameters. *Am J Cardiol.* 1990;66(21):13i-5i.
103. Khodneva Y, Shalev A, Frank SJ, Carson AP, Safford MM. Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study. *Diabetes Res Clin Pract.* 2016;115:115-21.
104. Ovalle F, Grimes T, Xu G, Patel AJ, Grayson TB, Thielen LA, et al. Verapamil and beta cell function in adults with recent-onset type 1 diabetes. *Nat Med.* 2018;24(8):1108-12.
105. Sjöden G, Rosenqvist M, Kriegholm E, Nordenström J, Björkhem I. Verapamil increases serum alkaline phosphatase in hypertensive patients. *J Intern Med.* 1990;228(4):339-42.
106. Schulte KL, Meyer-Sabellek WA, Haertenberger A, Thiede HM, Roecker L, Distler A, et al. Antihypertensive and metabolic effects of diltiazem and nifedipine. *Hypertension.* 1986;8(10):859-65.
107. Thulin T, Lehtonen A, Dahlöf C, Nilsson-Ehle P, Engqvist L, Lagerstedt C, et al. Long-term effects of diltiazem and atenolol on blood glucose, serum lipids, and

serum urate in hypertensive patients. Swedish-Finnish Study Group. *Int J Clin Pharmacol Ther.* 1999;37(1):28-33.

108. Søggaard P, Klausen IC, Rungby J, Faergeman O, Thygesen K. Lipoprotein(a) and oxygen free radicals in survivors of acute myocardial infarction: effects of captopril. *Cardiology.* 1996;87(1):18-22.

109. Kodama J, Katayama S, Tanaka K, Itabashi A, Kawazu S, Ishii J. Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. *Diabetes Care.* 1990;13(11):1109-11.

110. Rahmat J, Gelfand RL, Gelfand MC, Winchester JF, Schreiner GE, Zimmerman HJ. Captopril-associated cholestatic jaundice. *Ann Int Med.* 1985;102(1):56-8.

111. Leary WP, Reyes AJ, van der Byl KV, Acosta-Barrios TN. Effects of captopril, hydrochlorothiazide, and their combination on timed urinary excretions of water and solutes. *J Cardiovasc Pharmacol.* 1985;7 Suppl 1:S56-62.

112. Prince MJ, Stuart CA, Padia M, Bandi Z, Holland OB. Metabolic effects of hydrochlorothiazide and enalapril during treatment of the hypertensive diabetic patient. *Enalapril for hypertensive diabetics. Arch Intern Med.* 1988;148(11):2363-8.

113. Perani G, Muggia C, Martignoni A, Bongarzoni A, Radaelli A, Testa F, et al. Increase in plasma HDL-cholesterol in hypertensive patients treated with enalapril. *Clin Ther.* 1987;9(6):635-9.

114. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). *Circulation.* 2003;107(9):1291-6.

115. Seferovic JP, Claggett B, Seidelmann SB, Seely EW, Packer M, Zile MR, et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. *Lancet Diabetes Endocrinol.* 2017;5(5):333-40.
116. da Silva GH, Alves AV, Duques P, Seva-Pereira T, Soares EC, Escanhoela CA. Acute hepatotoxicity caused by enalapril: a case report. *J Gastrointest Liver Dis.* 2010;19(2):187-90.
117. Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. *Cardiovasc Drugs Ther.* 1987;1(1):29-38.
118. Bryant CE, Rajai A, Webb NJA, Hogg RJ. Effects of losartan and enalapril on serum uric acid and GFR in children with proteinuria. *Pediatr Nephrol.* 2021;36(10):3211-9.
119. Schieffer B, Bunte C, Witte J, Hoepfer K, Boger RH, Schwedhelm E, et al. Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease. *J Am Coll Cardiol.* 2004;44(2):362-8.
120. Droste HT, de Vries RA. Chronic hepatitis caused by lisinopril. *Neth J Med.* 1995;46(2):95-8.
121. Reyes AJ. Cardiovascular drugs and serum uric acid. *Cardiovasc Drugs Ther.* 2003;17(5-6):397-414.
122. Krysiak R, Basiak M, Okopien B. Impact of Lisinopril on Cardiometabolic Risk Factors in Men With Hypertension and Early-onset Androgenetic Alopecia: A Pilot Study. *J Cardiovasc Pharmacol.* 2021;78(5):e738-e42.
123. Yeung E, Wong FS, Wanless IR, Shiota K, Guindi M, Joshi S, et al. Ramipril-associated hepatotoxicity. *Arch Pathol Lab Med.* 2003;127(11):1493-7.

124. Labeeuw M, Pozet N, Zech PY, Hadj-Aissa A, Finaz de Villaine J, Laville M. [Influence of acute administration of ramipril on the excretion of uric acid]. *Arch Mal Coeur Vaiss.* 1987;80(6):870-4.
125. Ateya AM, El Hakim I, Shahin SM, El Borolossy R, Kreutz R, Sabri NA. Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial. *Hypertension.* 2022;79(8):1856-65.
126. Keilani T, Schlueter WA, Levin ML, Battle DC. Improvement of lipid abnormalities associated with proteinuria using fosinopril, an angiotensin-converting enzyme inhibitor. *Ann Intern Med.* 1993;118(4):246-54.
127. Nunes AC, Amaro P, Maç as F, Cipriano A, Martins I, Rosa A, et al. Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case report. *Eur J Gastroenterol Hepatol.* 2001;13(3):279-82.
128. Derici U, Sindel S, Arinsoy T, Bali M, Goker B, Cemri M, et al. Effects of verapamil slow release plus trandolapril combination therapy on essential hypertension. *Curr Ther Res Clin Exp.* 2003;64(1):10-20.
129. Würzner G, Gerster JC, Chioloro A, Maillard M, Fallab-Stubi CL, Brunner HR, et al. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. *J Hypertens.* 2001;19(10):1855-60.
130. Nygaard B, Strandgaard S. Marked hepatotoxicity associated with losartan treatment. *Blood Press.* 1996;5(3):190-1.
131. Sardo MA, Mandraffino G, Riggio S, D'Ascola A, Alibrandi A, Saitta C, et al. Effects of the angiotensin II receptor blocker losartan on the monocyte expression of biglycan in hypertensive patients. *Clin Exp Pharmacol Physiol.* 2010;37(9):933-8.

132. Top C, Cingözbay BY, Terekeci H, Küçükardali Y, Onde ME, Danaci M. The effects of valsartan on insulin sensitivity in patients with primary hypertension. *The J Int Med Res.* 2002;30(1):15-20.
133. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, et al. C-reactive protein in heart failure: prognostic value and the effect of valsartan. *Circulation.* 2005;112(10):1428-34.
134. Nakamura M, Sasai N, Hisatome I, Ichida K. Effects of irbesartan on serum uric acid levels in patients with hypertension and diabetes. *Clin Pharmacol.* 2014;6:79-86.
135. Persson F, Rossing P, Hovind P, Stehouwer CD, Schalkwijk C, Tarnow L, et al. Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy. *Diabetes.* 2006;55(12):3550-5.
136. Nishida Y, Takahashi Y, Nakayama T, Soma M, Kitamura N, Asai S. Effect of candesartan monotherapy on lipid metabolism in patients with hypertension: a retrospective longitudinal survey using data from electronic medical records. *Cardiovasc Diabetol.* 2010;9(1):38.
137. Wago T, Yoshimoto T, Akaza I, Tsuchiya K, Izumiyama H, Doi M, et al. Improvement of endothelial function in patients with hypertension and type 2 diabetes after treatment with telmisartan. *Hypertens Res.* 2010;33(8):796-801.
138. Satoh M, Tabuchi T, Minami Y, Takahashi Y, Itoh T, Nakamura M. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease. *Clin Ther.* 2009;31(10):2113-25.



139. Arao T, Okada Y, Mori H, Nishida K, Tanaka Y. Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension. *Endocr J.* 2013;60(5):563-70.
140. Derosa G, Maffioli P, Salvadeo SA, Ferrari I, Gravina A, Mereu R, et al. Differential effects of candesartan and olmesartan on adipose tissue activity biomarkers in type II diabetic hypertensive patients. *Hypertens Res.* 2010;33(8):790-5.
141. Rubio-Guerra AF, Garro-Almendaro AK, Elizalde-Barrera CI, Suarez-Cuenca JA, Duran-Salgado MB. Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients. *Ther Adv Cardiovasc Dis.* 2017;11(2):57-62.
142. Hosoya T, Kuriyama S, Yoshizawa T, Kobayashi A, Otsuka Y, Ohno I. Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. *Intern Med.* 2012;51(18):2509-14.
143. Zhang D, Huang QF, Li Y, Wang JG. Incident hyperuricemia in relation to antihypertensive therapy with the irbesartan/hydrochlorothiazide combination. *Blood Press Monit.* 2021;26(6):413-8.
144. Yagi S, Takashima A, Mitsugi M, Wada T, Hotchi J, Aihara K, et al. Effect of combination tablets containing amlodipine 10 mg and irbesartan 100 mg on blood pressure and cardiovascular risk factors in patients with hypertension. *Her Clin Risk Manag.* 2015;11:83-8.
145. Milionis HJ, Kakafika AI, Tsouli SG, Athyros VG, Bairaktari ET, Seferiadis KI, et al. Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia. *Am Heart J.* 2004;148(4):635-40.

146. Miller M, Dobs A, Yuan Z, Battisti WP, Borisute H, Palmisano J. Effectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-C. *Curr Med Res Opin.* 2004;20(7):1087-94.
147. Kim J, Lee HS, Lee KY. Effect of statins on fasting glucose in non-diabetic individuals: nationwide population-based health examination in Korea. *Cardiovasc Diabetol.* 2018;17(1):155.
148. Moutzouri E, Liberopoulos EN, Florentin M, Liamis G, Elisaf MS. Effects of statin monotherapy versus statin plus ezetimibe combination on serum uric acid levels. *J Cardiovasc Pharmacol Ther.* 2013;18(1):13-8.
149. Zhao L, Li S, Gao Y. Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis. *Ren Fail.* 2021;43(1):718-28.
150. Youssef F, Gupta P, Seifalian AM, Myint F, Mikhailidis DP, Hamilton G. The effect of short-term treatment with simvastatin on renal function in patients with peripheral arterial disease. *Angiology.* 2004;55(1):53-62.
151. Derosa G, Maffioli P, Reiner Ž, Simental-Mendía LE, Sahebkar A. Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis. *Drugs.* 2016;76(9):947-56.
152. Perez-Jimenez F, Hidalgo L, Zambrana JL, Arizon JM, Jimenez-Pereperez JA, Concha M, et al. Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients. *Am J Cardiol.* 1995;75(8):648-50.
153. Aranow C, Cush J, Bolster MB, Striebich CC, Dall'era M, Mackay M, et al. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. *Rheumatology.* 2020;59(7):1505-13.

154. Sasaki J, Otonari T, Uchida Y, Ikeda Y, Biro S, Kono S. Effects of pravastatin and atorvastatin on HDL cholesterol and glucose metabolism in patients with dyslipidemia and glucose intolerance: the PRAT study. *J Atheroscler Thromb.* 2013;20(4):368-79.
155. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. *J Am Coll Cardiol.* 2006;47(9):1803-10.
156. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. *JAMA.* 2001;286(1):64-70.
157. Alaupovic P, Attman PO, Knight-Gibson C, Mulec H, Weiss L, Samuelsson O. Effect of fluvastatin on apolipoprotein-defined lipoprotein subclasses in patients with chronic renal insufficiency. *Kidney Int.* 2006;69(10):1865-71.
158. Milionis HJ, Rizos E, Kostapanos M, Filippatos TD, Gazi IF, Ganotakis ES, et al. Treating to target patients with primary hyperlipidaemia: comparison of the effects of ATOrvastatin and ROSuvastatin (the ATOROS study). *Curr Med Res Opin.* 2006;22(6):1123-31.
159. Anagnostis P, Selalmatzidou D, Polyzos SA, Panagiotou A, Slavakis A, Panagiotidou A, et al. Comparative effects of rosuvastatin and atorvastatin on glucose metabolism and adipokine levels in non-diabetic patients with dyslipidaemia: a prospective randomised open-label study. *Inte J Clin Pract.* 2011;65(6):679-83.
160. Gonbert S, Malinsky S, Sposito AC, Laouenan H, Doucet C, Chapman MJ, et al. Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. *Atherosclerosis.* 2002;164(2):305-11.

161. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. *Circulation*. 2004;110(11):1406-12.
162. Basu A, Slama MQ, Nicholson WT, Langman L, Peyser T, Carter R, et al. Continuous Glucose Monitor Interference With Commonly Prescribed Medications: A Pilot Study. *J Diabetes Sci Technol*. 2017;11(5):936-41.
163. Thongtang N, Ai M, Otokozawa S, Himbergen TV, Asztalos BF, Nakajima K, et al. Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. *Am J Cardiol*. 2011;107(3):387-92.
164. Werida R, Khairat I, Khedr NF. Effect of atorvastatin versus rosuvastatin on inflammatory biomarkers and LV function in type 2 diabetic patients with dyslipidemia. *Biomed Pharmacother*. 2021;135:111179.
165. Mirjanic-Azaric B, Rizzo M, Jürgens G, Hallstroem S, Srdic S, Marc J, et al. Atorvastatin treatment increases plasma bilirubin but not HMOX1 expression in stable angina patients. *Scand J Clin Lab Invest*. 2015;75(5):382-9.
166. Ogata N, Fujimori S, Oka Y, Kaneko K. Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients. *Nucleosides Nucleotides Nucleic Acids*. 2010;29(4-6):321-4.
167. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. *Circulation*. 2001;103(9):1191-3.
168. Capoulade R, Chan KL, Yeang C, Mathieu P, Bossé Y, Dumesnil JG, et al. Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. *J Am Coll Cardiol*. 2015;66(11):1236-46.

169. Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. *J Atheroscl Thromb.* 2009;16(5):654-61.
170. Koshiyama H, Taniguchi A, Tanaka K, Kagimoto S, Fujioka Y, Hirata K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. *J Atheroscler Thromb.* 2008;15(6):345-50.
171. Feng T, Huang X, Liang Q, Liang Y, Yuan Y, Feng L, et al. Effects of Pitavastatin on Lipid-rich Carotid Plaques Studied Using High-resolution Magnetic Resonance Imaging. *Clin Ther.* 2017;39(3):620-9.
172. Ramires JA, Mansur AP, Solimene MC, Maranhão R, Chamone D, da Luz P, et al. Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia. *Int J Cardiol.* 1995;48(2):115-20.
173. Franceschini G, Calabresi L, Colombo C, Favari E, Bernini F, Sirtori CR. Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients. *Atherosclerosis.* 2007;195(2):385-91.
174. Ko HS, Kim CJ, Ryu WS. Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function. *J Cardiovasc Pharmacol.* 2005;46(4):405-11.
175. Damci T, Tatliagac S, Osar Z, Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. *Eur J Intern Med.* 2003;14(6):357-60.

176. Krysiak R, Gdula-Dymek A, Bachowski R, Okopien B. Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes. *Diabetes Care*. 2010;33(10):2266-70.
177. Angeles C, Lane BP, Miller F, Nord EP. Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity. *Am J Kidney Dis*. 2004;44(3):543-50.
178. Zhang J, Ji X, Dong Z, Lu J, Zhao Y, Li R, et al. Impact of fenofibrate therapy on serum uric acid concentrations: a review and meta-analysis. *Endocr J*. 2021;68(7):829-37.
179. Jung JY, Choi Y, Suh CH, Yoon D, Kim HA. Effect of fenofibrate on uric acid level in patients with gout. *Sci Rep*. 2018;8(1):16767.
180. Min YJ, Choi YH, Hyeon CW, Cho JH, Kim KJ, Kwon JE, et al. Fenofibrate reduces C-reactive protein levels in hypertriglyceridemic patients with high risks for cardiovascular diseases. *Korean Circ J*. 2012;42(11):741-6.
181. Sposito AC, Mansur AP, Maranhão RC, Rodrigues-Sobrinho CR, Coelho OR, Ramires JA. Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. *Braz J Med Biol Res*. 2001;34(2):177-82.
182. Sjöberg BG, Straniero S, Angelin B, Rudling M. Cholestyramine treatment of healthy humans rapidly induces transient hypertriglyceridemia when treatment is initiated. *Am J Physiol Endocrinol Metab*. 2017;313(2):E167-e74.
183. Superko HR, Greenland P, Manchester RA, Andreadis NA, Schectman G, West NH, et al. Effectiveness of low-dose colestipol therapy in patients with moderate hypercholesterolemia. *Am J Cardiol*. 1992;70(2):135-40.

184. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. *J Atheroscler Thromb.* 2010;17(1):37-44.
185. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langslet G, Bays H, et al. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol.* 2014;63(13):1278-88.
186. Bittner VA, Szarek M, Aylward PE, Bhatt DL, Diaz R, Edelberg JM, et al. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. *J Am Coll Cardiol.* 2020;75(2):133-44.
187. Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. *Heart Vessels.* 2008;23(2):91-5.
188. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceride levels after treatment with oral isotretinoin. A prospective study. *Arch Dermatol.* 1983;119(12):987-93.
189. De Marchi MA, Maranhão RC, Brandizzi LI, Souza DR. Effects of isotretinoin on the metabolism of triglyceride-rich lipoproteins and on the lipid profile in patients with acne. *Arch Dermatol Res.* 2006;297(9):403-8.
190. Webster GF, Webster TG, Grimes LR. Laboratory tests in patients treated with isotretinoin: occurrence of liver and muscle abnormalities and failure of AST and ALT to predict liver abnormality. *Dermatol Online J.* 2017;23(5).
191. de Morais TL, Giribela C, Nisenbaum MG, Guerra G, Mello N, Baracat E, et al. Effects of a contraceptive containing drospirenone and ethinylestradiol on blood

pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age. *Eur J Obstet Gynecol Reprod Biol.* 2014;182:113-7.

192. Winkler UH, Röhm P, Höschen K. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. *Contraception.* 2010;81(5):391-400.

193. Berenson AB, Rahman M, Wilkinson G. Effect of injectable and oral contraceptives on serum lipids. *Obstetrics and gynecology.* 2009;114(4):786-94.

194. Berenson AB, van den Berg P, Williams KJ, Rahman M. Effect of injectable and oral contraceptives on glucose and insulin levels. *Obstet Gynecol.* 2011;117(1):41-7.

195. Barkfeldt J, Virkkunen A, Dieben T. The effects of two progestogen-only pills containing either desogestrel (75 microg/day) or levonorgestrel (30 microg/day) on lipid metabolism. *Contraception.* 2001;64(5):295-9.

196. Borhan-Manesh F, Farnum JB. Methyltestosterone-induced cholestasis. The importance of disproportionately low serum alkaline phosphatase level. *Arch Int Med.* 1989;149(9):2127-9.

197. Kurahashi H, Watanabe M, Sugimoto M, Ariyoshi Y, Mahmood S, Araki M, et al. Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder. *Endocr J.* 2013;60(12):1321-7.

198. Zmunda JM, Thompson PD, Dickenson R, Bausserman LL. Testosterone decreases lipoprotein(a) in men. *Am J Cardiol.* 1996;77(14):1244-7.

199. Isotton AL, Wender MC, Casagrande A, Rollin G, Czepielewski MA. Effects of oral and transdermal estrogen on IGF1, IGFBP3, IGFBP1, serum lipids, and glucose



in patients with hypopituitarism during GH treatment: a randomized study. *Eur J Endocrinol.* 2012;166(2):207-13.

200. Mattiasson I, Rendell M, Törnquist C, Jeppsson S, Hulthén UL. Effects of estrogen replacement therapy on abdominal fat compartments as related to glucose and lipid metabolism in early postmenopausal women. *Horm Metab Res.* 2002;34(10):583-8.

201. Su W, Campos H, Judge H, Walsh BW, Sacks FM. Metabolism of Apo(a) and ApoB100 of lipoprotein(a) in women: effect of postmenopausal estrogen replacement. *J Clin Endocrinol Metab.* 1998;83(9):3267-76.

202. Lamon-Fava S, Posfai B, Asztalos BF, Horvath KV, Dallal GE, Schaefer EJ. Effects of estrogen and medroxyprogesterone acetate on subpopulations of triglyceride-rich lipoproteins and high-density lipoproteins. *Metabolism.* 2003;52(10):1330-6.

203. Raisz LG, Wiita B, Artis A, Bowen A, Schwartz S, Trahiotis M, et al. Comparison of the effects of estrogen alone and estrogen plus androgen on biochemical markers of bone formation and resorption in postmenopausal women. *J Clin Endocrinol Metab.* 1996;81(1):37-43.

204. Rymer J, Crook D, Sidhu M, Chapman M, Stevenson JC. Effects of tibolone on serum concentrations of lipoprotein(a) in postmenopausal women. *Acta Endocrinol (Copenh).* 1993;128(3):259-62.

205. de Beer F, Smelt AH, van Vark LC, Hoogerbrugge N, Havekes LM, Gevers Leuven JA. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia. *J Int Med.* 2002;251(2):148-55.

206. Eilertsen AL, Sandvik L, Steinsvik B, Sandset PM. Differential impact of conventional-dose and low-dose postmenopausal hormone therapy, tibolone and

raloxifene on C-reactive protein and other inflammatory markers. *J Thromb Haemost.* 2008;6(6):928-34.

207. Soma MR, Meschia M, Bruschi F, Morrisett JD, Paoletti R, Fumagalli R, et al. Hormonal agents used in lowering lipoprotein(a). *Chem Phys Lipids.* 1994;67-68:345-50.

208. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. *JAMA.* 1998;279(18):1445-51.

209. Shlipak MG, Simon JA, Vittinghoff E, Lin F, Barrett-Connor E, Knopp RH, et al. Estrogen and progestin, lipoprotein(a), and the risk of recurrent coronary heart disease events after menopause. *JAMA.* 2000;283(14):1845-52.

210. Sumino H, Ichikawa S, Kasama S, Takahashi T, Kumakura H, Takayama Y, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. *Atherosclerosis.* 2006;189(2):436-42.

211. Széplaki G, Varga L, Valentin S, Kleiber M, Karádi I, Romics L, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. *J Allergy Clin Immunol.* 2005;115(4):864-9.

212. Sanad Z, Ellakwa H, Desouky B. Comparison of alendronate and raloxifene in postmenopausal women with osteoporosis. *Climacteric.* 2011;14(3):369-77.

213. Piperi C, Kalofoutis C, Skenderi K, Economidou O, Kalofoutis A. Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women. *J Obstet Gynaecol.* 2004;24(4):414-9.

214. de Valk-de Roo GW, Stehouwer CD, Meijer P, Mijatovic V, Kluft C, Kenemans P, et al. Both raloxifene and estrogen reduce major cardiovascular risk factors in

healthy postmenopausal women: A 2-year, placebo-controlled study. *Arterioscler Thromb Vasc Biol.* 1999;19(12):2993-3000.

215. Denti L, Pasolini G, Cortellini P, Sanfelici L, Benedetti R, Cecchetti A, et al. Changes in HDL-cholesterol and lipoprotein Lp(a) after 6-month treatment with finasteride in males affected by benign prostatic hyperplasia (BPH). *Atherosclerosis.* 2000;152(1):159-66.

216. Edén S, Wiklund O, Oscarsson J, Rosén T, Bengtsson BA. Growth hormone treatment of growth hormone-deficient adults results in a marked increase in Lp(a) and HDL cholesterol concentrations. *Arterioscler Thromb.* 1993;13(2):296-301.

217. Lind S, Rudling M, Ericsson S, Olivecrona H, Eriksson M, Borgström B, et al. Growth hormone induces low-density lipoprotein clearance but not bile acid synthesis in humans. *Arterioscler Thromb Vasc Biol.* 2004;24(2):349-56.

218. Wang X, Magkos F, Patterson BW, Reeds DN, Kampelman J, Mittendorfer B. Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics. *Eur J Endocrinol.* 2012;167(2):217-23.

219. Ottens TH, Nijsten MW, Hofland J, Dieleman JM, Hoekstra M, van Dijk D, et al. Effect of high-dose dexamethasone on perioperative lactate levels and glucose control: a randomized controlled trial. *Critical Care.* 2015;19(1):41.

220. Abdelmannan D, Tahboub R, Genuth S, Ismail-Beigi F. Effect of dexamethasone on oral glucose tolerance in healthy adults. *Endocr Pract.* 2010;16(5):770-7.

221. Lindberg-Larsen V, Kehlet H, Bagger J, Madsbad S. Preoperative High-Dose Methylprednisolone and Glycemic Control Early After Total Hip and Knee

Arthroplasty: A Randomized, Double-Blind, Placebo-Controlled Trial. *Anesth Analg.* 2018;127(4):906-13.

222. Toncev G, Milicic B, Toncev S, Samardzic G. High-dose methylprednisolone therapy in multiple sclerosis increases serum uric acid levels. *Clin Chem Lab Med.* 2002;40(5):505-8.

223. Short KR, Bigelow ML, Nair KS. Short-term prednisone use antagonizes insulin's anabolic effect on muscle protein and glucose metabolism in young healthy people. *Am J Physiol Endocrinol Metab.* 2009;297(6):E1260-8.

224. Liu C, Zhen Y, Zhao Q, Zhai JL, Liu K, Zhang JX. Prednisone lowers serum uric acid levels in patients with decompensated heart failure by increasing renal uric acid clearance. *Can J Physiol Pharmacol.* 2016;94(7):797-800.

225. Bilic-Komarica E, Beciragic A, Junuzovic D. Effects of treatment with L-thyroxin on glucose regulation in patients with subclinical hypothyroidism. *Med Arch.* 2012;66(6):364-8.

226. Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. *Osteoporosis Int.* 2007;18(1):59-68.

227. Gattereau A, Vinay P, Biemann P, Davignon J, Lemieux G, Gougoux A. Effect of acute administration of salmon and human calcitonin on blood urate and renal excretion of uric acid in patients with Paget's disease of bone. *J Clin Endocrinol Metab.* 1979;49(4):635-7.

228. Ernst JA, Sy ER. Effect of azlocillin on uric acid levels in serum. *Antimicrob Agents Chemother.* 1983;24(4):609-10.

229. Papapetropoulou M, Giannoulaki E, Kastamonitis K, Siorokou T, Legakis J. Azlocillin and serum uric acid. *Chemioterapia.* 1986;5(2):113-5.

230. Zhou L, Bao J, Ma J. Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam. *Front Pharmacol.* 2019;10:1342.
231. Gresser U. Amoxicillin-clavulanic acid therapy may be associated with severe side effects -- review of the literature. *Eur J Med Res.* 2001;6(4):139-49.
232. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. *J Hepatol.* 2010;53(6):1049-53.
233. Peake M, Whiting M. Measurement of serum creatinine--current status and future goals. *Clin Biochem Rev.* 2006;27(4):173-84.
234. Martin E, Fanconi S, Kälin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone--bilirubin-albumin interactions in the neonate: an in vivo study. *Eur J Pediatr.* 1993;152(6):530-4.
235. Lee AJ, Maddix DS. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a patient with acute renal failure. *Ann Pharmacother.* 1997;31(6):727-32.
236. Hekimsoy Z, Biberoglu S, Cömlekçi A, Tarhan O, Mermut C, Biberoglu K. Trimethoprim/sulfamethoxazole-induced hypoglycemia in a malnourished patient with severe infection. *Eur J Endocrinol.* 1997;136(3):304-6.
237. Mah JK, Negreanu D, Radi S, Christopoulos S. Trimethoprim-sulfamethoxazole-induced refractory hypoglycaemia successfully treated with octreotide. *BMJ Case Rep.* 2021;14(5).
238. Polgreen PM, Putz D, Stapleton JT. Inaccurate glycosylated hemoglobin A1C measurements in human immunodeficiency virus-positive patients with diabetes mellitus. *Clin Infect Dis.* 2003;37(4):e53-6.
239. Chertow GM, Seifter JL, Christiansen CL, O'Donnell WJ. Trimethoprim-sulfamethoxazole and hypouricemia. *Clinical Nephrol.* 1996;46(3):193-8.

240. Martinez MA, Vuppalanchi R, Fontana RJ, Stolz A, Kleiner DE, Hayashi PH, et al. Clinical and histologic features of azithromycin-induced liver injury. *Clin Gastroenterol Hepatol*. 2015;13(2):369-76.e3.
241. Syal K, Srinivasan A, Banerjee D. Streptomycin interference in Jaffe reaction - possible false positive creatinine estimation in excessive dose exposure. *Clin Biochem*. 2013;46(1-2):177-9.
242. Althaqafi A, Ali M, Alzahrani Y, Ming LC, Hussain Z. How Safe are Fluoroquinolones for Diabetic Patients? A Systematic Review of Dysglycemic and Neuropathic Effects of Fluoroquinolones. *Ther Clin Risk Manag*. 2021;17:1083-90.
243. Mitchell RT, Marshall LH, Lefkowitz LB, Jr., Stratton CW. Falsely elevated serum creatinine levels secondary to the presence of 5-fluorocytosine. *Am J Clin Pathol*. 1985;84(2):251-3.
244. Takasu N, Yamada T, Miura H, Sakamoto S, Korenaga M, Nakajima K, et al. Rifampicin-induced early phase hyperglycemia in humans. *Am Rev Respir Dis*. 1982;125(1):23-7.
245. Murthy GD, Byron D, Shoemaker D, Visweswaraiiah H, Pasquale D. The utility of rifampin in diagnosing Gilbert's syndrome. *Am J Gastroenterol*. 2001;96(4):1150-4.
246. Louthrenoo W, Hongsongkiat S, Kasitanon N, Wangkaew S, Jatuworapruk K. Effect of Antituberculous Drugs on Serum Uric Acid and Urine Uric Acid Excretion. *J Clin Rheumatol*. 2015;21(7):346-8.
247. Derby LE, Gutthann SP, Jick H, Dean AD. Liver disorders in patients receiving chlorpromazine or isoniazid. *Pharmacotherapy*. 1993;13(4):353-8.
248. Pham AQ, Doan A, Andersen M. Pyrazinamide-induced hyperuricemia. *P T*. 2014;39(10):695-715.

249. Solangi GA, Zuberi BF, Shaikh S, Shaikh WM. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. *J Coll Physicians Surg Pak.* 2004;14(3):136-8.
250. Postlethwaite AE, Kelley WN. Studies on the mechanism of ethambutol-induced hyperuricemia. *Arthritis Rheum.* 1972;15(4):403-9.
251. Albright ES, Ovalle F, Bell DS. Artificially low hemoglobin A1c caused by use of dapsons. *E Endocr Pract.* 2002;8(5):370-2.
252. Berthold HK, Parhofer KG, Ritter MM, Addo M, Wasmuth JC, Schliefer K, et al. Influence of protease inhibitor therapy on lipoprotein metabolism. *J Int Med.* 1999;246(6):567-75.
253. Shafran SD, Mashinter LD, Roberts SE. The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. *HIV Med.* 2005;6(6):421-5.
254. Lee GA, Rao M, Mulligan K, Lo JC, Aweeka F, Schwarz JM, et al. Effects of ritonavir and amprenavir on insulin sensitivity in healthy volunteers. *AIDS.* 2007;21(16):2183-90.
255. Ishigami M, Hayashi K, Katano Y, Itoh A, Hirooka Y, Goto H. Impact of early elevation of serum bilirubin during treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C. *Hepatol Res.* 2010;40(10):963-70.
256. Robertson M. Artificially low HbA1c associated with treatment with ribavirin. *BMJ.* 2008;336(7642):505.
257. Doyle MA, Galanakis C, Mulvihill E, Crawley A, Cooper CL. Hepatitis C Direct Acting Antivirals and Ribavirin Modify Lipid but not Glucose Parameters. *Cells.* 2019;8(3).

258. Voigt E, Wasmuth JC, Vogel M, Mauss S, Schmutz G, Kaiser R, et al. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results. *Infection*. 2004;32(2):82-8.
259. Lee GA, Seneviratne T, Noor MA, Lo JC, Schwarz JM, Aweeka FT, et al. The metabolic effects of lopinavir/ritonavir in HIV-negative men. *AIDS*. 2004;18(4):641-9.
260. Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, et al. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers. *HIV Med*. 2009;10(5):318-27.
261. Saif MW, McGee PJ. Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. *JOP*. 2005;6(4):369-74.
262. Matheke ML, Kessler G, Chan KM. Interference of the chemotherapeutic agent etoposide with the direct phosphotungstic acid method for uric acid. *Clin Chem*. 1987;33(11):2109-10.
263. Gupta B, LeVea C, Litwin A, Fakhri MG. Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. *Clin Colorectal Cancer*. 2007;6(6):447-9.
264. Onishi Y, Hatae M, Matsuda Y, Nakamura T, Kodama Y, Itoh M, et al. [Severe hyperbilirubinemia after cisplatin-based chemotherapy]. *Gan To Kagaku Ryoho*. 1995;22(8):1103-6.
265. Marani TM, Trich MB, Armstrong KS, Ness PM, Smith J, Minniti C, et al. Carboplatin-induced immune hemolytic anemia. *Transfusion*. 1996;36(11-12):1016-8.



266. Noronha V, Burtness B, Murren J, Duffy TP. Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. *Clinical Colorectal Cancer*. 2005;5(4):283-6.
267. Hwangbo Y, Lee EK. Acute Hyperglycemia Associated with Anti-Cancer Medication. *E Endocrinol Metab*. 2017;32(1):23-9.
268. Zumoff B. The hypouricemic effect of o,p'-DDD. *Am J Med Sci*. 1979;278(2):145-7.
269. Cheung TK, Lo KW, Lam CW, Lau W, Lam PK. A crossover study of triptorelin and leuprorelin acetate. *Fertil Steril*. 2000;74(2):299-305.
270. Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. *Fertil Steril*. 2002;77(4):684-92.
271. Joensuu H, Holli K, Oksanen H, Valavaara R. Serum lipid levels during and after adjuvant toremifene or tamoxifen therapy for breast cancer. *Breast Cancer Res Treat*. 2000;63(3):225-34.
272. Kusama M, Miyauchi K, Aoyama H, Sano M, Kimura M, Mitsuyama S, et al. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. *Breast Cancer Res Treat* 2004;88(1):1-8.
273. Liu CL, Yang TL. Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. *Breast Cancer Res Treat*. 2003;79(1):11-6.
274. Shewmon DA, Stock JL, Rosen CJ, Heiniluoma KM, Hogue MM, Morrison A, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. *Arterioscler Thromb*. 1994;14(10):1586-93.

275. Bonanni B, Johansson H, Gandini S, Guerrieri-Gonzaga A, Sandri MT, Mariette F, et al. Effect of tamoxifen at low doses on ultrasensitive C-reactive protein in healthy women. *J Thromb Haemost.* 2003;1(10):2149-52.
276. Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. *Jpn J Clin Oncol.* 2010;40(7):627-33.
277. Diamanti-Kandarakis E, Mitrakou A, Raptis S, Tolis G, Duleba AJ. The effect of a pure antiandrogen receptor blocker, flutamide, on the lipid profile in the polycystic ovary syndrome. *J Clin Endocrinol Metab.* 1998;83(8):2699-705.
278. Gomez JL, Dupont A, Cusan L, Tremblay M, Suburu R, Lemay M, et al. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients. *Am J Med.* 1992;92(5):465-70.
279. Naeem M, Bacon BR, Mistry B, Britton RS, Di Bisceglie AM. Changes in serum lipoprotein profile during interferon therapy in chronic hepatitis C. *Am J Gastroenterol.* 2001;96(8):2468-72.
280. Constantinescu CS, Freitag P, Kappos L. Increase in serum levels of uric acid, an endogenous antioxidant, under treatment with glatiramer acetate for multiple sclerosis. *Mult Scler.* 2000;6(6):378-81.
281. Yilmaz VT, Kocak H, Dinckan A, Cetinkaya R. New-Onset Diabetes Mellitus Associated with Sirolimus Use in Renal Transplant Recipients. *Eurasian J Med.* 2015;47(3):213-5.
282. Perez-Ruiz F, Nolla JM. Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis. *J Clin Rheumatol.* 2003;9(4):215-8.

283. Bálint A, Farkas K, Szűcs M, Szepes Z, Nagy F, Wittmann T, et al. Long-term increase in serum cholesterol levels in ulcerative colitis patients treated with cyclosporine: an underdiagnosed side effect frequently associated with other drug-related complications. *Scand J Gastroenterol*. 2014;49(1):59-65.
284. Lin HY, Rocher LL, McQuillan MA, Schmaltz S, Palella TD, Fox IH. Cyclosporine-induced hyperuricemia and gout. *N Eng J Med*. 1989;321(5):287-92.
285. McCune TR, Thacker LR, II, Peters TG, Mulloy L, Rohr MS, Adams PA, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. *Transplantation*. 1998;65(1):87-92.
286. Kanbay M, Akcay A, Huddam B, Usluogullari CA, Arat Z, Ozdemir FN, et al. Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients. *Transplant Proc*. 2005;37(7):3119-20.
287. Kelley WN, Rosenbloom FM, Seegmiller JE. The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. *J Clin Invest*. 1967;46(9):1518-29.
288. Lee JJ, Bykerk VP, Dresser GK, Boire G, Haraoui B, Hitchon C, et al. Reduction in Serum Uric Acid May Be Related to Methotrexate Efficacy in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort (CATCH). *Clin Med Insights Arthritis Musculoskelet Disord*. 2016;9:37-43.
289. Lilien LD, Srinivasan G, Yeh TF, Pildes RS. Decreased plasma glucose following indomethacin therapy in premature infants with patent ductus arteriosus. *Pediatr Pharmacol*. 1985;5(1):73-7.

290. Hosono S, Ohno T, Kimoto H, Nagoshi R, Shimizu M, Nozawa M. Reduction in blood glucose values following indomethacin therapy for patent ductus arteriosus. *Pediatrics Int.* 1999;41(5):525-8.
291. Meyer O, Hoffmann T, Aslan T, Ahrens N, Kiesewetter H, Salama A. Diclofenac-induced antibodies against RBCs and platelets: two case reports and a concise review. *Transfusion.* 2003;43(3):345-9.
292. Kim SB, Kim SH, Chang JW, Lee SK, Min WK, Chi HS, et al. Effects of celecoxib on high-sensitivity C-reactive protein in chronic peritoneal dialysis patients. *Renal Fail.* 2004;26(4):381-4.
293. Monakier D, Mates M, Klutstein MW, Balkin JA, Rudensky B, Meerkin D, et al. Rofecoxib, a COX-2 inhibitor, lowers C-reactive protein and interleukin-6 levels in patients with acute coronary syndromes. *Chest.* 2004;125(5):1610-5.
294. Iqbal U, Siddiqui HU, Anwar H, Chaudhary A, Quadri AA. Allopurinol-Induced Granulomatous Hepatitis: A Case Report and Review of Literature. *J Investig Med High Impact Case Rep.* 2017;5(3):2324709617728302.
295. Fontana RJ, Li YJ, Phillips E, Saeed N, Barnhart H, Kleiner D, et al. Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. *Liver Int.* 2021;41(8):1884-93.
296. Nishiyama T, Yokoyama T, Hanaoka K. Liver function after sevoflurane or isoflurane anaesthesia in neurosurgical patients. *Can J Anaesth.* 1998;45(8):753-6.
297. Lorsomradee S, Cromheecke S, Lorsomradee S, De Hert SG. Effects of sevoflurane on biomechanical markers of hepatic and renal dysfunction after coronary artery surgery. *J Cardiothorac Vasc Anesth.* 2006;20(5):684-90.

298. Obata R, Bito H, Ohmura M, Moriwaki G, Ikeuchi Y, Katoh T, et al. The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function. *Anesth Analg*. 2000;91(5):1262-8.
299. Ozlü O, Ozkara HA, Eris S, Ocal T. Propofol anaesthesia and metabolic acidosis in children. *Paediatr Anaesth*. 2003;13(1):53-7.
300. Routh JI, Paul WD. Assessment of interference by aspirin with some assays commonly done in the clinical laboratory. *Clin Chem*. 1976;22(6):837-42.
301. Ranga GS, Kalra OP, Tandon H, Gambhir JK, Mehrotra G. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. *J Stroke Cerebrovasc Dis*. 2007;16(5):220-4.
302. Camargo JL, Stiff J, Gross JL. The effect of aspirin and vitamins C and E on HbA1c assays. *Clin Chim Acta*. 2006;372(1-2):206-9.
303. Chen Y, Li J, Ou Z, Zhang Y, Liang Z, Deng W, et al. Association between aspirin-induced hemoglobin decline and outcome after acute ischemic stroke in G6PD-deficient patients. *CNS Neurosci Ther*. 2021;27(10):1206-13.
304. Caspi D, Lubart E, Graff E, Habet B, Yaron M, Segal R. The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients. *Arthritis Rheum*. 2000;43(1):103-8.
305. Nigam PK, Chandra A. Positive and negative false estimates of serum creatinine. *Interv Cardiol*. 2017;9(4):163-7.
306. Basu A, Veetil S, Dyer R, Peyser T, Basu R. Direct Evidence of Acetaminophen Interference with Subcutaneous Glucose Sensing in Humans: A Pilot Study. *Diabetes Technol Ther*. 2016;18 Suppl 2(Suppl 2):S243-7.
307. Wilding P, Heath DA. Effect of paracetamol on uric acid determination. *Ann Clin Biochem*. 1975;12(4):142-4.

308. Kumagai Y, Song ID, Maeda M, Tanaka R, Sakamoto Y, Aso M, et al. Effect of High Dose Acetaminophen on Liver Function Tests in Healthy Subjects. *Clin Ther.* 2017;39(8):e5-e6.
309. Maeda M, Tanaka R, Aso M, Sakamoto Y, Song I, Ochiai M, et al. Hepatic Adaptation to Therapeutic Doses of Acetaminophen: An Exploratory Study in Healthy Individuals. *Clin Ther.* 2020;42(7):1276-91.e1.
310. Seifert CF, Anderson DC. Acetaminophen usage patterns and concentrations of glutathione and gamma-glutamyl transferase in alcoholic subjects. *Pharmacotherapy.* 2007;27(11):1473-82.
311. Sonmez FM, Demir E, Orem A, Yildirmis S, Orhan F, Aslan A, et al. Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes. *J Child Neurol.* 2006;21(1):70-4.
312. Hunter J, Thompson RP, Rake MO, Williams R. Controlled trial of phetharbital, a non-hypnotic barbiturate, in unconjugated hyperbilirubinaemia. *Br Med J.* 1971;2(5760):497-9.
313. Gough H, Goggin T, Crowley M, Callaghan N. Serum bilirubin levels with antiepileptic drugs. *Epilepsia.* 1989;30(5):597-602.
314. Xiang R, Xu J, Yu H, Chen Q, Huang Y, Li Z, et al. Effects of carbamazepine and sodium valproate on efficacy, cognitive function and uric acid in epileptic patients with first generalized seizure. *Am J Ttransl Res.* 2021;13(8):9778-83.
315. Ring HA, Heller AJ, Marshall WJ, Johnson AL, Reynolds EH. Plasma uric acid in patients receiving anticonvulsant monotherapy. *Epilepsy Res.* 1991;8(3):241-4.
316. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Influence of stable, long-term treatment with phenobarbital on the activity of serum alanine aminotransferase and gamma-glutamyltransferase. *Br J Biomed Sci.* 2008;65(3):132-5.

317. Thurmon TF, Robertson KP, Anderson EE. Phenobarbital and alkaline phosphatase: A preliminary report. *J Pediatr.* 1972;81(3):547-9.
318. Tardivel S, Banide H, Porembaska Z, Dupuis Y, Aymard P, Lacour B. In vitro inhibition of alkaline phosphatase activities from intestine, bone, liver, and kidney by phenobarbital. *Enzyme.* 1992;46(6):276-83.
319. Carter BL, Small RE, Mandel MD, Starkman MT. Phenytoin-induced hyperglycemia. *Am J Hosp Pharm.* 1981;38(10):1508-12.
320. Krause KH, Berlit P, Schmidt-Gayk H, Schellenberg B. Antiepileptic drugs reduce serum uric acid. *Epilepsy Res.* 1987;1(5):306-7.
321. Aldenhövel HG. The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase. *Eur Arch Psychiatry Neurol Sci.* 1988;237(5):312-6.
322. Keefe EB, Sunderland MC, Gabourel JD. Serum gamma-glutamyl transpeptidase activity in patients receiving chronic phenytoin therapy. *Dig Dis Sci.* 1986;31(10):1056-61.
323. Aggarwal A, Kumar M, Faridi MM. Effect of carbamazepine on serum lipids and liver function tests. *Indian Pediatr.* 2005;42(9):913-8.
324. Herink M, Ito MK. Medication Induced Changes in Lipid and Lipoproteins. [Updated 2018 May 10]. In: Feingold KR, Anawalt B, Boyce A, et al., eds. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.;2000. [cited 2022 Oct 18]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK326739/>
325. Babacan O, Karaoglu A, Vurucu S, Yesilkaya E, Yesilyurt O, Cayci T, et al. May long term oxcarbazepine treatment be lead to secondary hyperparathyroidism? *J Clin Neurol.* 2012;8(1):65-8.

326. Attilakos A, Voudris KA, Garoufi A, Mastrogianni S, Dimou S, Prassouli A, et al. Effect of sodium valproate monotherapy on serum uric acid concentrations in ambulatory epileptic children: a prospective long-term study. *Eur J Paediatr Neurol*. 2006;10(5-6):237-40.
327. Hadzagic-Catibusic F, Hasanbegovic E, Melunovic M, Zubcevic S, Uzicanin S. Effects of Carbamazepine and Valproate on Serum Aspartate Aminotransferase, Alanine Aminotransferase and Gamma - Glutamyltransferase in Children. *Med Arch*. 2017;71(4):239-42.
328. Boluk A, Guzelipek M, Savli H, Temel I, Ozişik HI, Kaygusuz A. The effect of valproate on bone mineral density in adult epileptic patients. *Pharmacol Res*. 2004;50(1):93-7.
329. Koçer A, Dikici S, Atakay S, Okuyucu S. Serum uric acid and lipid levels while taking topiramate for migraine. *Headache*. 2008;48(7):1056-60.
330. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. *Clin Pharmacol Ther*. 1970;11(6):883-9.
331. Gaertner I, Altendorf K, Batra A, Gaertner HJ. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. *J Clin Psychopharmacol*. 2001;21(2):215-22.
332. Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, et al. Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. *Biol Psychiatry*. 2009;66(11):1013-22.



333. Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. *Schizophr Res.* 2009;107(2-3):115-21.
334. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. *Am J Psychiatry.* 2003;160(2):290-6.
335. Diaz FJ, Pérez-Iglesias R, Mata I, Martínez-García O, Vázquez-Barquero JL, de Leon J, et al. Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample. *Schizophr Res.* 2010;121(1-3):207-12.
336. Cohen S, Fitzgerald B, Okos A, Khan S, Khan A. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. *J Clin Psychiatry.* 2003;64(1):60-2.
337. Zhang H, Li H, Shu L, Gu N, Wang G, Weng Y, et al. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia. *Neuropsychiatr Dis Treat.* 2011;7:77-85.
338. Jena M, Mishra A, Mishra BR, Nath S, Maiti R. Effect of lurasidone versus olanzapine on cardiometabolic parameters in unmedicated patients with schizophrenia: a randomized controlled trial. *Psychopharmacology.* 2020;237(11):3471-80.
339. Shalev A, Hermesh H, Munitz H, Birger M. Chlorprothixene-induced hypouricemia: a biologic indicator of drug compliance. *J Clin Psychiatry.* 1989;50(11):424-7.
340. Shalev A, Hermesh H, Munitz H. The hypouricemic effect of chlorprothixene. *Clin Pharm Ther.* 1987;42(5):562-6.

341. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. *Schizophr Res.* 2003;59(1):49-57.
342. Smith RC, Lindenmayer JP, Bark N, Warner-Cohen J, Vaidhyanathaswamy S, Khandat A. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. *T Int J Neuropsychopharmacol.* 2005;8(2):183-94.
343. Krakowski M, Czobor P, Citrome L. Weight gain, metabolic parameters, and the impact of race in aggressive inpatients randomized to double-blind clozapine, olanzapine or haloperidol. *Schizophr Res.* 2009;110(1-3):95-102.
344. Smith RC, Lindenmayer JP, Davis JM, Kelly E, Viviano TF, Cornwell J, et al. Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study. *J Clin Psychiatry.* 2009;70(11):1501-13.
345. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. *Prog Neuropsychopharmacol Biol Psychiatry.* 2007;31(6):1255-60.
346. Fathian F, Gjestad R, Kroken RA, Løberg EM, Reitan SK, Fleischhacker WW, et al. Association between C-reactive protein levels and antipsychotic treatment during 12 months follow-up period after acute psychosis. *Schizophr Res.* 2022;241:174-83.
347. Hefner G, Shams ME, Unterecker S, Falter T, Hiemke C. Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. *Psychopharmacology.* 2016;233(9):1695-705.

348. Muti M, Del Grande C, Musetti L, Marazziti D, Turri M, Cirronis M, et al. Serum uric acid levels and different phases of illness in bipolar I patients treated with lithium. *Psychiatry Res.* 2015;225(3):604-8.
349. Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. *Clin Neuropharmacol.* 2012;35(5):244-53.
350. Chan HY, Lin AS, Chen KP, Cheng JS, Chen YY, Tsai CJ. An open-label, randomized, controlled trial of zotepine and risperidone for acutely ill, hospitalized, schizophrenic patients with symptoms of agitation. *J Clin Psychopharmacol.* 2013;33(6):747-52.
351. Koller D, Almenara S, Mejía G, Saiz-Rodríguez M, Zubiaur P, Román M, et al. Metabolic Effects of Aripiprazole and Olanzapine Multiple-Dose Treatment in a Randomised Crossover Clinical Trial in Healthy Volunteers: Association with Pharmacogenetics. *Adv Ther.* 2021;38(2):1035-54.
352. Uher R, Tansey KE, Dew T, Maier W, Mors O, Hauser J, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. *Am J Psychiatry.* 2014;171(12):1278-86.
353. Pan SJ, Tan YL, Yao SW, Xin Y, Yang X, Liu J, et al. Fluoxetine induces lipid metabolism abnormalities by acting on the liver in patients and mice with depression. *Acta Pharmacol Sin.* 2018;39(9):1463-72.
354. Chavda N, Kantharia ND, Jaykaran. Effects of fluoxetine and escitalopram on C-reactive protein in patients of depression. *J Pharmacol Pharmacother.* 2011;2(1):11-6.

355. Paslakis G, Kopf D, Westphal S, Gilles M, Lederbogen F, Hamann B, et al. Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. *J Psychopharmacol*. 2011;25(10):1344-6.
356. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. *Clin Pharm Ther*. 2009;86(5):527-32.
357. Guhan AR, Cooper S, Osborne J, Lewis S, Bennett J, Tattersfield AE. Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects. *Thorax*. 2000;55(8):650-6.
358. Bremner P, Woodman K, Burgess C, Crane J, Purdie G, Pearce N, et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. *Eur Respir J*. 1993;6(2):204-10.
359. Arnman K, Carlström S, Thorell JI. The effect of norepinephrine and theophylline on blood glucose, plasma FFA, plasma glycerol and plasma insulin in normal subjects. *Acta Med Scand*. 1975;197(4):271-4.
360. Morita Y, Nishida Y, Kamatani N, Miyamoto T. Theophylline increases serum uric acid levels. *J Allergy Clin Immunol*. 1984;74(5):707-12.
361. Chertoff J, Alam S, Clark V. Cyproheptadine-Induced Acute Liver Failure. *ACG Case Rep J*. 2014;1(4):212-3.
362. Malaguarnera M, Vacante M, Russo C, Dipasquale G, Gargante MP, Motta M. A single dose of rasburicase in elderly patients with hyperuricaemia reduces serum uric acid levels and improves renal function. *Expert Opin Pharmacother*. 2009;10(5):737-42.

363. German P, Liu HC, Szwarcberg J, Hepner M, Andrews J, Kearney BP, et al. Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function. *J Acquir Immune Defic Syndr*. 2012;61(1):32-40.
364. Lecoultre V, Egli L, Theytaz F, Despland C, Schneiter P, Tappy L. Fructose-induced hyperuricemia is associated with a decreased renal uric acid excretion in humans. *Diabetes Care*. 2013;36(9):e149-50.
365. Fukao K, Shimada K, Hiki M, Kiyonagi T, Hirose K, Kume A, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between azelnidipine and amlodipine on glucose tolerance and endothelial function--a crossover trial (AGENT). *Cardiovasc Diabetol*. 2011;10:79.
366. Herrington DM, Pusser BE, Riley WA, Thuren TY, Brosnihan KB, Brinton EA, et al. Cardiovascular effects of droloxifene, a new selective estrogen receptor modulator, in healthy postmenopausal women. *Arterioscler Thromb Vasc Biol*. 2000;20(6):1606-12.
367. Yamamoto T, Moriwaki Y, Takahashi S, Nasako Y, Higashino K. Effect of lactate infusion on renal transport of purine bases and oxypurinol. *Nephron*. 1993;65(1):73-6.